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Section I 
Introduction and summary of outputs
Context
The 2012 work programme aims to achieve the twin objectives of ensuring that the 
commitments detailed in the 2010–12 strategy are delivered and that sound foundations 
are laid for the agency to take on the challenges it will face in the 2013–15 period. It is 
therefore an important year for both planning and substantive activities. In 2012, some 
developmental activities will reach key milestones and new products addressing critical 
aspects of the European drug situation will be released. These activities will supplement 
the core analysis provided through the EMCDDA´s annual reporting exercise and thereby 
ensure that the agency continues to provide a comprehensive review of the current European 
drug situation, through a set of high-quality products tailored to the differing needs of 
policymakers, practitioners, researchers and scientists, as well as the general public. It is 
important to note that the achievements envisaged in this work programme are only possible 
with the active participation and support of the Reitox network of national focal points who 
are the principal providers of data for the agency’s outputs.
During 2012, the work programme and strategy for 2013–15 needs to be prepared and 
approved. The EMCDDA’s work will remain governed by the founding regulation and its 
recast, but activities will need to be revised to remain relevant to the current drug situation 
and policy developments. The EMCDDA will need to consider the findings of the external 
evaluation of the agency that will become available during 2012. Moreover, given that part 
of the agency’s work is to support the information needs arising from EU level coordination 
and cooperation activities, the implications of the future policy framework that will supersede 
the current drug strategy and its action plans will need to be carefully considered.  
The Council Decision on new psychoactive substances that provides the legal basis for the 
work conducted to implement the European early-warning system is under review. The initial 
phase of this work was an assessment of the mechanism and was conducted by the European 
Commission in 2011. In 2012, discussions on the future development and strengthening of 
this mechanism will continue and the EMCDDA will contribute with technical input where 
appropriate and if required, and will track developments carefully so as to ensure that 
the current early-warning system remains functional and that any necessary adjustments to 
working practices are made.
The EMCDDA’s planning needs to be sensitive to external factors that impact on its work 
and the work of its key partners in the Member States. Foremost among these is the current 
financial situation which has seen resources available for data collection and monitoring 
come under increasing pressure across the European Union. The financial perspectives for 
the EMCDDA also mean that any new developments have to be accomplished within a fixed, 
or possibly even smaller, resource envelope. This provides an even stronger incentive for 
ensuring that the EMCDDA data collection and reporting strategy is efficient and productive. 
Scarce resources must be invested wisely and priorities need to reflect contemporary needs. 
The work programme for 2012 embraces this perspective; it is realistic in its ambitions and 
reflective in its focus on ensuring that the overall system is fit for purpose and in line with the 
key information needs of the European Union.
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The resources required for implementing the 2012 work programme will be provided by the 
EMCDDA budget for 2012, as adopted by its Management Board, on the basis of the decision 
of the Budgetary Authority on the EC annual subsidy to the EMCDDA’s budget. The EC annual 
subsidy on which the 2012 EMCDDA budget relies is expected to amount to EUR 15 550 920. 
This work programme has been drawn up on the basis of this estimate. Changes in the monies 
available to the EMCDDA to fulfil its mission would require adjustments to be made to the 
activities proposed here.
Highlights of the 2012 work programme 
 
An overarching theme of the three-year work programme (2010–12) is the need to adopt a 
more efficient and integrated approach to data management and analysis. Considerable 
progress has been made in this area and is visible in the Fonte system, the supporting data 
warehouse and the existence of a dedicated data management and statistical support team.  
The EMCDDA now benefits from a dramatically increased capacity to manage the submission 
and handling of quantitative data. In 2012, the focus of activities will be: to extend the current 
concept to qualitative and textual data; to assist national focal points in developing tailored 
solutions for the submission of large data sets; and to develop more robust quality assurance 
standards for generating and reporting estimates and composite numbers. 
 
For core activities related to monitoring the drug situation and responses, 2012 will see the 
conclusion of a number of developmental projects. Of particular note are the review activities on 
the key indicators on treatment demand (TDI) and on problem drug use (PDU). More generally, 
attention will continue to be given to developing analysis that combines response and situational 
data sets. The response indicators will be rationalised into a new composite model and a second 
detailed baseline assessment of the state of implementation of the five epidemiological key 
indicators will be completed. Activities planned to support data collection by Member States 
include a mentoring project on estimation techniques and a new methodological toolkit to 
support studies monitoring risk behaviours and infections among drug injectors. Moreover, two 
strategies important for the future of the agency’s work will be finalised in 2012: an overall 
internal strategy for treatment monitoring and a new strategy for monitoring and reporting on 
issues related to drug use in prison. A European overview of interventions in prison settings will 
also be published as a Selected issue accompanying the 2012 Annual report. 
 
Three new publications in the Insights series will review important aspects of how Europe is 
responding to drug problems. The first will provide a state-of-the-art overview of current scientific 
understanding of models of addiction, including the link between substance use and behavioural 
disorders. This will be accompanied by publications exploring two response areas where 
information sources at the EU level remain relatively underdeveloped: the social rehabilitation of 
those with drug problems and the role of therapeutic communities as treatment providers.  
A timely addition to the EMCDDA’s Scientific Monograph series will be the release of a scientific 
overview of issues related to the production and use of new groups of psychoactive substances. 
 
Over the last two years, the availability and use of new psychoactive substances has attracted 
rising policy, professional and public interest and concern. The EMCDDA has become 
recognised as a global leader in the provision of information and analysis on this topic. 
Activities conducted in partnership with Europol on the European early-warning system (EWS)  
on new drugs therefore remain a priority in 2012. Particular attention will be given to the 
maintenance of the rapid information exchange mechanism and its supporting database and 
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tools. The EMCDDA will also continue to audit the information available on the use and health 
implications of these new substances and continue the development of methods to monitor the 
Internet retail market for ‘legal highs’. Organisationally, EWS activities will be more closely 
coordinated with epidemiological work on identifying important changes in patterns of drug use. 
Collectively, these activities will enable the EMCDDA to fulfil its commitment to identifying and 
reporting on trends more rapidly. The issue is relevant to changes in patterns of drug use for 
established drugs as well as new substances. Methodological and substantive work will be 
undertaken to improve the responsiveness of the current information system to new developments. 
One ground-breaking example is the use of wastewater analysis to provide a low-cost and rapid 
indicator of changes in drug availability in selected European cities. Following up on recent 
legislation in this area, the exchange of data on the misuse of medicines between the EMCDDA 
and the European Pharmacovigilance system (operated by the European Medicines Agency) will 
be consolidated. 
 
One of the objectives of the 2010–12 strategy is to improve the availability, quality and 
comparability of indicators of drug supply, supply reduction and crime. This is linked to a 
requirement to better understand the illicit drug market and drug availability across the EU and 
the EMCDDA is working in close partnership with the European Commission and Europol to 
advance this objective. Following on from a first European conference held in Brussels in 2010, 
the EMCDDA has established technical working groups that will report back at a second 
consensus-building conference in 2012. The conference is jointly organised by the European 
Commission and the EMCDDA and, for the first time, will define European key indicators in this 
area. This is an important step to improving supply information to support policy formation. 
 
Identifying and disseminating best practice and the related topic of identifying model guidelines 
and standards for interventions are important developmental topics in 2012. This area has 
benefited from a recent project supported by the European Commission (Study on the 
development of an EU framework for minimum quality standards and benchmarks in drug 
demand reduction — EQUS). The EMCDDA recognises that partnership and consensus-building 
are key aspects to working effectively in this area and will continue to work in close 
collaboration with the Commission. The agency will also cooperate with the Cochrane 
Collaboration and with appropriate EU and international agencies. Concretely, the EMCDDA 
will continue to develop its web-based tools and resources on best practice, update and develop 
its reviews of scientific evidence to guide intervention development, and produce a number of 
new guidelines, including one that addresses working with substance-abusing pregnant women, 
a project planned in association with the World Health Organisation (WHO). Guidelines will be 
developed for assessing and responding to drug-related medical emergencies occurring in 
recreational settings, which is an issue of growing importance in many countries. 
 
Guidelines on how to evaluate national drug strategies and action plans will also be published. 
These guidelines result from the scaling-up of work to monitor and support the evaluation of 
European drug policies through the establishment of a unit focused on policy. New activities in 
this area include giving greater attention to the role of civil society in drug policy formation.  
A new case study of national experience in the policy field will be published in the Drug policy 
profiles series. A technical paper providing a comparative analysis of international policy 
developments will also be released. Of particular contemporary relevance is the preparation of a 
new Selected issue on the impact of the current economic situation on drug services. In the area 
of laws and the legal basis for interventions, an index allowing comparison of drug laws applied 
in various Member States will be finalised. Collection and analysis of information on two new 
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topics will be conducted in 2012: the first will describe the typologies, mechanisms and use of 
alternatives to punishment in practice in the Member States and the second will inform on the 
range of penalties for comparable trafficking quantities. 
 
As an information agency, communication is a key aspect of the EMCDDA’s work. In 2012, the 
challenge for the communication team remains to ensure that outputs are of high quality and 
configured to the different audiences of the agency’s work. As web-based communication grows 
ever more important, special attention is given to the further development of the EMCDDA’s 
online and multimedia resources. The increased productivity of the agency in recent years means 
that efficient tracking, scheduling and quality control of products are essential and internal 
procedures in this area will be strengthened. 
 
Delivering excellent results while ensuring efficient use of the agency’s resources is only possible 
with effective management and sound decision-making processes. To achieve this, the work of 
the Management Board will be supported and prompt follow-up assured on the decisions and 
recommendations made. At the same time, the internal organisation and work processes will be 
fine-tuned in 2012, following the consolidation in 2011 of the new EMCDDA structure. While 
the Heads of unit (HoU) meetings will provide support to the Director in making the strategic 
decisions, the Internal coordination group set up in 2011 will consolidate its role as a platform 
to discuss operational matters and provide input to the HoU meetings. Ensuring that the agency’s 
resources are used in the most efficient, effective and economical manner will remain a priority. 
Apart from the ongoing ex-ante verifications of financial operations, an assessment of existing 
working processes will be made in 2012, with a view to rationalising use of resources and 
improving performance. Further developing the in-house planning, monitoring and performance 
evaluation system is a key organisational objective. A series of important projects and initiatives 
will take place in this area. A new three-year strategy will be developed by the agency and 
adopted by the Management Board. The main priorities for the work of the EMCDDA, together 
with the goals, main objectives and performance indicators will be defined. At the same time, 
the end-term evaluation of the current strategy and work programme (2010–12) will be prepared 
and launched. A new ICT tool for managing information related to the EMCDDA´s events will be 
implemented. This tool will allow centralised data collection and analysis of events and will 
improve reporting on and dissemination of the agency´s activities. 
 
With regard to the Reitox network of national focal points (NFPs), the current three-year strategy 
defines two main objectives: first, to prepare and implement a Reitox development strategy 
aimed at consolidating the network and improving its perceived added value at national level; 
and second, to streamline operational and control processes including introducing an electronic 
tool for grants and project management. In 2012, priority will be given to the added value of 
the work of NFPs at EU and national level. To this end, the implementation of the Reitox 
development strategy, started in previous years, will move forward, and a ‘Reitox focus groups’ 
initiative will be launched. This will be supported by the new structure of the Reitox meeting, 
following the concept developed in 2011. Within this framework, the first ‘Reitox week’ will be 
organised in May 2012, encouraging NFPs to develop partnerships and build new projects and 
initiatives. At the same time, to streamline operational and control processes, the new dedicated 
information management system will be fully implemented, ensuring strong and high-quality 
financial and administrative management of the grant agreements. 
 
The ability to produce high-quality scientific outputs depends on an efficient and well-functioning 
administrative and technical infrastructure. The EMCDDA has been actively developing its 
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internal systems for planning, monitoring, risk assessment and quality assurance. This work will 
continue in 2012. As is the case with all EU agencies, there is an ongoing need to ensure the 
agency’s administrative processes reflect current EU regulations and recognised good practices. 
The EMCDDA is proactive in this area and committed to maintaining its status as a lead agency 
in implementing necessary measures to ensure good governance. 
 
Technical and administrative tasks can only be performed efficiently if internal information 
technology systems are fully functional. Ensuring high-quality services in this area can be 
challenging for decentralised agencies and the EMCDDA is therefore particularly fortunate to 
benefit from a strong information technology support team who work closely with technical and 
administrative staff to ensure information technology needs are understood and appropriate 
solutions introduced. In 2012, along with ongoing improvements and developments to the 
infrastructure, attention will be given to web-based resources. 
 
Partnership and added value 
 
The EMCDDA’s results are only possible through partnership with national data providers and 
experts as well as with relevant EU bodies and international organisations. As already 
mentioned, the Reitox network of national focal points are the principal data providers for the 
agency’s outputs and strong collaboration with them is essential for the EMCDDA’s success.  
The Reitox network represents a unique feature of the European drug information system. It not 
only allows comparable data to be collected in all Member States but also provides an important 
mechanism for feedback and for ensuring that analyses produced by the agency are grounded 
in an understanding of the unique national situations that exist across the EU. The capacity for 
rapid bilateral information exchange provided by the Reitox network is increasingly 
demonstrated in the growth of early-warning and trend-spotting activities. A number of activities 
will be undertaken in 2012 to support capacity development in national focal points and to 
further improve the mechanisms existing for data submission and exchange.   
 
The EMCDDA recognises the benefits and efficiency that comes through joint work with other 
institutional partners. Added value at the EU level comes from joined-up working practices and 
products can have additional authority and value when they are endorsed by the key institutions 
working in the area. In 2012, the EMCDDA will continue to prioritise working in partnership for 
operational analysis and for establishing guidelines and standards with other relevant European 
agencies. Of particular note here are the joint analyses and information sharing activities 
conducted with Europol, the European Centre for Disease Prevention and Control (ECDC) and 
the European Medicines Agency (EMA). In recognition of the increasingly global nature of the 
drugs problem and the EMCDDA’s role as a conduit to and source of European technical 
expertise and experience, the agency will continue its cooperation in appropriate areas with the 
international agencies working on drug issues, most importantly, but not limited to the United 
Nations Office on Drugs and Crime (UNODC) and the World Health Organisation (WHO). 
Partnerships will also be pursued at the technical and scientific level. The EMCDDA has areas  
of common interest with a number of non-EU based centres of excellence in drug monitoring and 
research, and will contribute to a global review of the existing scientific evidence base on  
drug-impaired driving. Within Europe, the closer working relationship with the ESPAD (European 
school survey project on alcohol and other drugs) agreed in 2011 will result in the joint 
publication of the summary report of the 2011 ESPAD survey. The ESPAD data set now provides 
one of the best longitudinal windows for tracking drug trends in Europe and there is substantial 
added value in bringing this data resource into the broader context of EMCDDA reporting.
I.  Introduction and summary of outputs
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Structure of the work programme 
 
This work programme has been developed from a detailed planning exercise completed by 
each of the agency’s units. The exercise has been informed by the requirements of the three-
year work programme and strategy (2010–12) and guided by the agency’s founding regulation 
and its recast. To make this top-level document accessible, each area has been broken down 
by substantive area and ongoing core activities are distinguished from developmental ones. 
For each area, the specific objectives are accompanied by their related activities and expected 
outcomes. This new structure is the result of the ongoing rationalisation of planning processes 
and procedures taking place within the EMCDDA. It should be noted that some outcomes, 
especially those related to specific analyses, are indicative as they depend on the results of 
preliminary interrogation of the data. Activities under the risk assessment of new psychoactive 
substances depend on actual need. As the EMCDDA has to respond to important ad hoc 
information requests and new developments, some flexibility is built into the planning process, 
along with regular reviews to ensure that resources are being used optimally and important 
emerging information needs are being met.
Outputs to be published in 2012 and their intended audience 
Output Policy Other target audiences
Science Practice Citizen
Annual reporting
Annual report on the state of the drugs problem 
in Europe  
(printed, PDF, online, 23 languages)
x x x x
Selected issues
•	Drug-using parents
•	Drugs and prison  
•	Drugs and tourism 
(printed, PDF, EN with summary in 23  
languages)
x x x
Statistical bulletin
(online, EN)
x x
Technical publications
Drugs in focus policy briefings 
•	Minimum quality standards of interventions 
•	Drug-related research 
(printed, PDF, 25 languages)
x
EMCDDA Monographs
•	New groups of psychoactive substances in 
Europe 
(printed, PDF, EN with summary in 23  
languages)
x x
EMCDDA Insights 
•	 Therapeutic communities in Europe
•	Models of addiction
•	Social reintegration and reduction of social 
exclusion of drug users
(printed, PDF, EN with summary in 23  
languages)
x x x
EMCDDA Manuals 
•	 European guidelines for the evaluation of 
national drug strategies 
(printed, PDF, EN)
x x
Joint publications
EMCDDA–Europol joint publications
•	 The European ecstasy market
(printed, PDF, EN)
x x x
ESPAD 2011 summary  
(printed, PDF, 23 languages)
x x x
I.  Introduction and summary of outputs
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Output Policy Other target audiences
Science Practice Citizen
Outputs related to the implementation of the 
Council Decision 2005/387/JHA
•	 EMCDDA–Europol report on the  
implementation of the Decision (Article 10 
report)
•	 EMCDDA–Europol joint report  
(if appropriate)
•	 EMCDDA Risk assessments (if appropriate)
•	 Profiles: National early-warning systems
(printed, PDF, EN)
•	 The European database on new drugs 
(EDND)
(online, restricted)
x x
EMCDDA National drug policy profiles
•	National drug policy profiles, No. 2
x x
EMCDDA Thematic papers
•	New methods in analysing and evaluat-
ing prevention interventions (EU-US cross-
analysis)
•	Voices of adolescent cannabis users
•	 Report on drug policy advocacy groups in 
Europe
•	Analysis of the development of EU drug 
policy documents
•	 Inventory and comparative analysis of  
international and regional drug strategies  
(EU, OAS, etc.)
•	 Estimates of public expenditure related to 
detainees for drug-law offences
(PDF, EN)
 
x 
 
 
x 
 
x 
 
x 
 
 
x
 
x 
 
 
x 
 
x 
 
x 
 
 
x
 
x 
 
x
 
 
 
x
Web-based tools and resources
Ongoing development and content updating 
of the EMCDDA’s public website. This includes 
regular and cyclical content updating including:
•	Statistical bulletin
•	Country overviews and other country data
•	Best practice portal (including EIB and  
EDDRA) 
•	News and events
•	 Topical content areas (policy and law, health 
and social interventions, indicator resources 
pages, research, drug profiles, etc.)
New content:
•	New drug profiles (if appropriate)
•	New topic areas
(online, EN, with some multilingual sections)
x x x x
Work programme 2012
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Output Policy Other target audiences
Science Practice Citizen
EMCDDA institutional publications
General report of activities x x
EMCDDA 2013–15 strategy and work  
programme
x x
EMCDDA 2013 work programme x x
Drugnet Europe newsletter  
(printed and online, EN, four issues)
x x x x
In addition to the key products listed above, a number of outputs for which the work has been completed in 
2011 will be released. A series of technical reports will also be produced in 2012, details of which can be 
found in Section II. Please note that the list for the thematic papers and the technical reports is indicative and 
may be revised if necessary to take into account ongoing operational and/or technical factors, or to allow 
the agency to adjust its activities to respond to any important emerging information needs. 
II
Section II 
Monitoring and reporting on the drugs problem in 
Europe
II.1. Data collection, analysis and quality assurance
Overview
Each year, a major EMCDDA task is managing the annual cycle of data submission, analysis 
and reporting. The result of this process is the Annual reporting package which consists of 
linked outputs that form the basic information set from which many of the agency’s other 
products are derived.
Managing these core activities represents a major component of the EMCDDA’s annual work 
programme. As the system has developed in both coverage and completeness, the volume of 
data being processed has increased considerably. In terms of data acquisition, over 400 000 
new data points are added annually and the agency also has to process and analyse a large 
volume of text-based material. Therefore, improving the efficiency of the data management 
process and quality assurance are ongoing priorities for the EMCDDA as is ensuring that our 
approach to analysis is rigorous, appropriately documented and scientifically sound.
To achieve this, in 2012 the infrastructure for data analysis will be maintained and further 
improved. Procedures, systems and tools will continue to be refined to ensure data quality,  
to increase the efficiency of analytical processes and to ensure the smooth production of  
high-quality outputs. Measures to increase the harmonisation and standardisation of processes 
are also planned for 2012 in the areas of data collection and validation and data processing 
and analysis. In addition, the EMCDDA will begin to rationalise its approach to the coding, 
manipulation and analysis of qualitative data sets.
An important aspect of work in this area is the need to support national focal points (NFPs) 
with the submission process. This requires an annual review and revision (where necessary) 
of tools and protocols. Capacity-building and support activities are also planned for 2012 
and efforts will be made to address the needs of focal points so as to increase their capacity 
for the automatic electronic transfer of information. Attention will be given to rationalising 
presentations of country-specific data. 
Improvements to the quality assurance mechanisms will also be implemented in 2012. 
These improvements will build upon the already considerable consultation, validation and 
checking work that is carried out annually. A review of our statistical methods will be 
concluded and this will help improve the standard of statistical outputs. Particular attention 
will be given to refining the procedures that ensure the consistency of data used in different 
EMCDDA products and that ensure that composite numbers are appropriately constructed and 
documented. 
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Specific objective Activities Expected outputs/results
A. Core activities
Data collection and management
II.1.1. Further develop and improve the 
data collection infrastructure and the 
management of Fonte
II.1.1.1. Ongoing management of Fonte and 
of the Data warehouse
•	 Infrastructure for drug data analysis  
maintained and improved 
II.1.1.2. Construct templates, including  
validation rules, and contribute to the  
formulation of new data collection instruments 
•	Data collection instruments in a range of 
formats, including templates for each of 
the standard tables, available to the NFPs 
on time
II.1.2. Continue to develop and improve 
the data collection processes and data 
quality assurance mechanisms 
II.1.2.1. Conduct automatic and manual 
validation of the reports submitted, in close 
collaboration with the NFPs
•	Valid and reliable data in Fonte and the 
Data warehouse
II.1.2.2. Monitor the quality of the data 
reported by the NFPs and provide feedback 
and support to improve reporting processes 
•	Consistency of data between the various 
data collection tools
•	30 Quality reports prepared and  
submitted on time to NFPs
II.1.3. Continue to build the capacity of 
the NFPs in the area of data management 
and reporting
II.1.3.1. Organise the follow-up on the Fonte 
training of May 2011
•	 Training organised and supporting  
documents available
Data analysis and statistical support
II.1.4. Implement all the data analysis  
and statistical support processes  
necessary to report in 2012 on the  
situation and responses in Europe (Annual 
report, Statistical bulletin, Country  
overviews and other EMCDDA  
publications)
II.1.4.1. Carry out the analysis of data on the 
European drug situation and responses, and 
draft the content of the Annual report
•	Data analysis conducted and Annual report 
drafted
II.1.4.2. Prepare the Statistical bulletin •	Statistical bulletin prepared and  
published on the EMCDDA website
II.1.4.3. Prepare the Country overviews •	30 Country overviews prepared and  
published on the EMCDDA website
II.1.4.4. Update and maintain the web 
resources
•	Web resources updated
B. New developmental areas
II.1.5. Continue to build the capacity of 
the NFPs in the area of data management 
and reporting
II.1.5.1. Provide technical support to NFPs 
with the automatic submission of data,  
especially for TDI
•	Automatic submission of data for TDI for 5 
additional countries
•	 Improved knowledge of data availability 
relating to treatment within 5 countries
II.1.6. Improve the quality control of  
statistical outputs and further ensure  
transparency of calculations
II.1.6.1. Conduct a review of the calculations 
in the Statistical bulletin and the Annual report
•	 Report on the appropriateness of methods 
and processes prepared
•	 Improved quality control of statistical output
•	 External validation of statistical methods 
adopted
II.1.6.2. Check consistency of data between 
the Statistical bulletin tables and the various 
publications
•	Data consistency and validity across  
EMCDDA publications
II.1.7. Improve the quality assurance 
cycle, based on the conclusions of the 
ongoing internal and external review 
exercises
II.1.7.1. Develop a proposal to improve the 
quality assurance cycle, in consultation with 
NFPs
•	 Proposal developed and presented at the 
Heads of national focal points (HNFPs) 
meeting in November 2012
II.1.8. Revise and adapt the Country  
overviews on the drugs situation in EU 
Member States, based on the  
conclusions of the ongoing internal and 
external review exercises
II.1.8.1. Assess the current process for  
preparing the Country overviews and develop 
a new structure for the product
•	New structure developed and adopted  
in-house
Work programme 2012
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II.2. Key indicators and monitoring the epidemiology of the drug 
situation
Overview
In the area of key indicators (KIs) and monitoring the epidemiology of the drug situation,  
the work to maintain and develop the European expert networks for the five key indicators 
will continue, through the organisation of annual expert meetings and the provision of 
technical and scientific advice to the NFPs and other national experts. Each European KI 
meeting is a two-day event attended by 40–50 experts, with satellite workshops organised 
prior to or after the meeting. Together, these meetings gather each year around 200–250 
experts from the Member States along with experts from other countries (such as the US, 
Canada, Australia, Russia) and representatives of European bodies and international 
organisations. The key indicators are increasingly used by other organisations to which the 
EMCDDA also provides advice and support.  
 
A number of methodological improvements are planned for 2012. First, a detailed second 
key indicator assessment will be carried out as a follow-up to the baseline exercise conducted 
in 2009, implying the analysis of the five key indicators in each EMCDDA Member State. 
In order to assist the NFPs in the implementation of the (revised) key indicators, support 
programmes including training activities and on-site assistance will be developed. In addition, 
improvements will be made to the methods used to assess problem cannabis use in population 
surveys, as well as in the methods to estimate the prevalence of drug injection based on the 
treatment demand indicator (TDI) and problem drug use (PDU) data. In the area of general 
population surveys (GPS), a number of methodological developments will be continued from 
previous years, such as GPS questionnaire mapping and the consolidation of the harmonised 
data group. In the area of drug-related deaths (DRD), analytical capacity on mortality cohorts 
will be boosted, and in the area of drug-related infectious diseases (DRID), analytical capacity 
on existing data will be further reinforced. 
 
The collaboration with the ESPAD schools project will be further strengthened in 2012.  
One of the main results of this cooperation will be the publication of the ESPAD 2011 
summary report.
 
II.2.2. General population surveys (GPS) 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.2.2.1. Further develop the GPS KI 
methodology
II.2.2.1.1. Develop project to evaluate costs 
and benefits of online data collection tools to 
implement GPS
•	 Project report prepared
II.2.2.1.2. Develop project to explore and 
document non-response in GPS
•	 Project report prepared
II.2.2.1.3. Consolidate the GPS questionnaire 
map
•	Map of questions used in recent national 
GPS questionnaires consolidated, validated 
and published on the website (KI portal)
II.2.2.2. Strengthen collaboration with the 
ESPAD schools project
II.2.2.2.1. Participate in ESPAD meetings,  
provide support for methodological  
developments, joint analysis and enhanced 
dissemination of ESPAD findings
•	 ESPAD 2011 summary report published
B. New developmental areas
II.2.2.3. Develop European analytical 
capacity in GPS and thematic outputs
II.2.2.3.1. Consolidate and expand the GPS 
harmonised data group 
•	 Project report prepared
II.2.2.3.2. Carry out analysis in areas under 
development: psychoactive medicines;  
polydrug use; perceived availability 
•	 Technical reports prepared
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II.2.1. Key indicators — ongoing work 
 
Specific objective Activities Expected outputs/results
II.2.1.1. Maintain and develop the  
European expert networks on key  
indicators (KIs)
II.2.1.1.1. Organise the annual European 
expert meeting/conference for each key  
indicator (GPS, TDI, DRID, DRD, PDU) with  
experts from all Member States, candidate 
and potential candidate countries and  
international organisations 
•	Annual EU expert meetings organised for 
all five KIs
•	Supporting documents available
II.2.1.2. Evaluate the level of  
implementation of KIs in all Member 
States
II.2.1.2.1. Carry out assessment of the KI 
implementation for each country and for each 
KI (GPS, TDI, DRD, DRID, PDU)
•	Assessment carried out for each country 
150 assessment reports prepared  
(5 reports, one for each KI, for each of the 
30 EMCDDA Member States)
II.2.1.3. Steer and promote improvements 
in KI implementation and reporting
II.2.1.3.1. Provide scientific and technical 
advice and support to national experts and 
the NFPs
•	 EMCDDA support provided as needed, 
concrete results to be defined based on the 
specific requests
II.2.1.4. Ensure dissemination of updated 
KIs methodology to broader professional 
and scientific community
II.2.1.4.1. Maintain and update the restricted 
web area and the public website (KI gateway)
•	Web area (restricted and public) updated
II.2.1.5. Promote analytical potential and 
outputs of epidemiological key indicators
II.2.1.5.1. Develop proposals and prototypes 
to increase use of already existing KI  
information
•	 Internal working document prepared
II.2.3. Treatment demand indicator (TDI) 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.2.3.1. Steer and promote  
implementation of TDI revision 
II.2.3.1.1. Organise small expert group  
meeting on piloting the implementation of the 
TDI revision
•	Meeting organised and supporting  
documents available
II.2.3.1.2. Continue assessment of national 
TDI data collection instruments and TDI item 
lists 
•	 Table of comparison between national data 
collection instruments and TDI item list 
II.2.3.2. Define and put into operation a 
support programme for the implementation 
of the new TDI protocol
II.2.3.2.1. Organise training activities and 
provide on-site support to NFPs
•	At least 50% of NFPs ready to implement 
the core components from 1 January 2013
II.2.4. Drug-related deaths indicator (DRD) 
 
Specific objective Activities Expected outputs/results
B. New developmental areas
II.2.4.1. Support European analysis of 
special mortality registries (SR)
II.2.4.1.1. Analyse the characteristics of DRD 
cases recorded in SRs
•	 Project report prepared
II.2.4.2. Support European analysis of 
mortality cohort studies 
II.2.4.2.1. Analyse combined national  
datasets of cohort studies (comparison of 
cohort studies for 4–5 countries)
•	Article submitted to scientific journal 
 II.2.4.2.2. Organise workshop for data 
analysis and assessment of the use of the 
2011 revised cohort protocol 
•	Workshop organised and supporting  
documents available
 II.2.4.3. Analyse methadone drug-related 
deaths 
 II.2.4.3.1. Collect and analyse data with the 
national experts
•	 Technical report prepared
 II.2.4.4. Analyse health consequences 
related to cannabis and cocaine
 II.2.4.4.1. Review the data from hospital 
emergency services available in National 
reports
•	 Internal working document prepared
 
II.2.5. Problem drug use (PDU) 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.2.5.1. Steer and promote improvements 
in KI implementation and reporting
II.2.5.1.1. Provide technical support for PDU 
implementation in selected countries  
•	 Project report prepared
•	 Training provided in selected countries
II.2.5.1.2. Conduct revision of the guidelines 
to estimate prevalence and incidence of 
problem drug use 
•	 Internal working document prepared
II.2.5.1.3. Carry out mapping survey on 
current barriers to IDU estimation and outline 
possible solutions
•	 Internal working document prepared
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Specific objective Activities Expected outputs/results
B. New developmental areas
II.2.5.2. Ensure ongoing PDU revision and 
improvement
II.2.5.2.1. Develop project to explore possible 
interpolation of trends based on routine data 
•	 Project report prepared
II.2.5.2.2. Conduct literature review on  
scientific evidence to support the PDU revision
•	 Project report prepared
•	 Technical report prepared
II.2.5.2.3. Complete the PDU  
reconceptualisation framework
•	 Internal working document prepared
•	 Endorsement of framework by national 
experts and NFPs
II.2.5.3. Establish monitoring of intensive 
forms of cannabis use/cannabis disorders 
at EU level
II.2.5.3.1. Carry out advanced combined  
European analysis of national validation  
studies of cannabis dependence scales
•	At least 2 articles submitted to scientific 
journals
•	 Project report prepared
II.2.5.3.2. Develop EU guidelines/ 
recommendations on intensive forms of  
cannabis use
•	 Internal working document prepared
 
II.2.6. Drug-related infectious diseases indicator (DRID) 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.2.6.1. Develop and improve the DRID 
guidance tools 
II.2.6.1.1. Prepare base modules of the DRID 
toolkit 
•	 Three modules completed
II.2.6.2. Maintain DRID early-warning 
system
II.2.6.2.1. Provide rapid response to DRID 
outbreaks and other threats, early warnings 
•	Quick feedback to Member States, EC and 
ECDC, and dissemination where  
appropriate to wider expert network
II.2.6.3. Contribute to external analyses 
and international cooperation
II.2.6.3.1. Contribute EMCDDA data and  
interpretation on viral hepatitis in IDUs to 
ECDC European review on viral hepatitis
•	 EMCDDA contribution to the ECDC  
publication
B. New developmental areas
II.2.6.4. Explore options for expanding 
DRID to new areas  
II.2.6.4.1. Review and analyse existing data 
at the EMCDDA on behavioural surveillance 
among IDUs
•	 Internal working document prepared
II.2.6.4.2. Review key new areas regarding 
HCV in IDUs and identify research needs and 
public health implications
•	 Paper submitted to scientific journal
II.2.6.4.3. Conduct analysis on infectious 
diseases, drugs and sex risk in MSM (based 
on data from the European MSM Internet 
Survey, EMIS)
•	 Project report prepared
•	 Technical report prepared
II.2.6.5. Ensure coordination of the DRID 
modelling network and data infrastructure
II.2.6.5.1. Finalise and publish modelling 
analyses from last project phase
•	 Two articles submitted to scientific journal
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II.2.7. Cross-indicator analyses 
 
Specific objective Activities Expected outputs/results
II.2.7.1. Develop multi-indicator trend 
analysis at the EMCDDA
II.2.7.1.1. Develop in-house working group 
on multi-indicator trend analysis, mixing  
qualitative and quantitative data
•	Working group set up
•	 Improved trend analysis in the Annual 
report and other products
II.2.7.1.2. Prepare a technical paper on 
mixed methods analysis with monitoring data
•	 Technical report prepared
II.2.7.2. Develop methods of estimation of 
prevalence of drug injection based on TDI 
and PDU data
II.2.7.2.1. Carry out analysis of existing TDI 
data on drug injection to estimate prevalence 
of drug injectors through combining it with 
PDU estimation
•	 Project report prepared
•	 Technical report prepared
II.2.7.3. Develop cross-indicator analysis 
DRD and PDU
II.2.7.3.1. Analyse DRD in relation to PDU 
and IDU prevalence estimations
•	 Internal working document prepared
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II.3. Monitoring demand reduction responses, interventions and 
solutions applied to drug-related problems
Overview
As is the case each year, routine analytical work will be carried out to report on the demand 
reduction activities implemented at EU leveI. Furthermore, to ensure a better understanding 
of the availability, accessibility and quality of responses to drug use in Europe, several 
thematic publications will be released. These include three EMCDDA Insights on therapeutical 
communities in Europe, models of addiction, and the social reintegration and reduction of 
social exclusion of drug users. 
 
In order to develop and explore potential new data sources on drug treatment and harm 
reduction, a review of the national treatment systems in Europe will be prepared, followed by 
a modelling exercise aimed at improving data collection among main non-specialist health 
and social responses (HSR) providers. In the field of health and social responses, the work 
on developing indicators will be consolidated and finalised in light of the EMCDDA treatment 
data collection strategy, to be completed during the year. 
 
In 2012, the EMCDDA will also support the work of DG SANCO to prepare the analysis 
necessary for the second progress report on implementing the Council Recommendation 
on the prevention and reduction of health-related harm associated with drug dependence 
of 18 June 2003. The work to be undertaken is directly relevant to, and extends the scope 
of, activities to assess the implementation of harm-reduction interventions across the EU. 
The project will benefit from and contribute to the ongoing monitoring of harm-reduction 
interventions in Europe and will allow EMCDDA staff to share their expertise and work closely 
with external contractors avoiding duplication of effort. The EMCDDA, working in close 
coordination with European Commission activities and other relevant partners, will continue to 
support the technical development of guidelines and good practice standards. In this context, 
the development of guidelines on pregnancy and substance use in cooperation with WHO is 
envisaged and scoping work is planned to inform the development of guidelines related to 
needs assessment within the prison setting. 
 
In the area of prevention, the developmental work will focus on early intervention, especially 
for alcohol and cannabis, and on prevention services for ethnic minorities (to support action 
20 of the EU drugs action plan, 2009–12). New methods in analysing and evaluating 
prevention interventions will also be presented. 
 
The Best practice portal is a resource for professionals, policymakers and researchers in the 
drugs field. It provides information on the available evidence on drug-related prevention, 
treatment and harm-reduction activities focusing on the European context. In 2012, the 
Best practice portal will be further developed to respond to the growing needs of the target 
audience. Among others, this will involve conducting systematic reviews of evidence to 
support improvement of the portal. This will provide the stakeholders (scientific community, 
practitioners and methodologists) with an accumulating body of information on the main 
aspects of quality, promotion and implementation and will help answer relevant questions 
coming from the countries. A review of the research supporting evidence-based interventions 
will also be carried out to identify the gaps and to publish a list of possible studies needed. 
The EMCDDA Insights publications will support quality in the interventions area through 
providing information on latest evidence and practice. 
II.3.1. Treatment 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.3.1.1. Exploit available data for  
improved reporting on EU  
demand-reduction activities
II.3.1.1.1. Publish online health and social 
responses national overviews covering  
treatment responses and availability,  
harm-reduction responses and social  
reintegration
•	Online health and social responses  
national overviews compatible and 
integrated in the new EMCDDA website 
concept
II.3.1.2. Develop an analytical framework 
that provides a better understanding of 
the availability, accessibility and quality of 
responses to drug use in Europe
II.3.1.2.1. Estimate ‘access to treatment’ 
based on consolidated datasets and literature 
review
•	 Project report prepared
•	 Technical report prepared
II.3.1.2.2. Assess and follow up the impact of 
the introduction of new types of treatment.  
Review evidence, assess quality and  
availability (cannabis treatment)
•	 Internal working document prepared
II.3.1.2.3. Finalise and publish the Selected 
issue on ‘Drug-using parents’
•	Selected issue published
II.3.1.2.4. Carry out preparatory work for 
the 2013 Selected issue ‘Residential care in 
Europe’
•	 Preparatory work, including development 
of guidelines, conducted as planned
II.3.1.3. Improve understanding of drug 
use in the context of models of  
dependency and compulsive behaviour
II.3.1.3.1 Finalise the EMCDDA Insight on 
models of addiction
•	 EMCDDA Insight published
B. New developmental areas
II.3.1.2. Develop and explore potential 
new data sources on drug treatment and 
harm reduction
II.3.1.2.5. Implement consultant study on 
‘Assessment of the European and national 
estimates of the total number of drug users in 
treatment’ and develop harmonised  
description of national treatment systems in 
Europe
•	 Project reports prepared
•	 Technical report prepared (part of the  
treatment data collection strategy)
II. 3.1.2.6. Design, launch and implement 
consultant study to develop ‘toolkit’ to estimate 
treatment provision, including by specialist 
HSR providers (e.g. General Practitioners and 
low-threshold agencies)
•	 Project report prepared
•	 Technical report prepared (part of the  
treatment data collection strategy
II.3.1.4. Further conceptualise social 
reintegration within the health and social 
responses area
II.3.1.4.1. Finalise the EMCDDA Insight on 
social reintegration and reduction of social 
exclusion of drug users
•	 EMCDDA Insight published
II.3.1.5. Gain better understanding of the 
availability and application of the  
therapeutic community model in Europe
II.3.1.5.1. Finalise the EMCDDA Insight on 
therapeutic communities for the rehabilitation 
of drug users in Europe
•	 EMCDDA Insight published
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II.3.2. Harm reduction 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.3.2.1. Exploit available data to provide 
a comprehensive report on EU  
harm-reduction activities
II.3.2.1.1. Provide technical support to the 
studies and research initiatives funded by 
the EC (DG SANCO), (specifically the 2nd 
progress report on Council Recommendation 
of 18 June 2003), as requested
•	Contribution to EC report on  
implementation of the Council  
Recommendation
II.3.2.2. Rationalise data collection  
approaches and tools for harm reduction 
into a coherent set of responses indicators
II.3.2.2.1. Finalise harm-reduction indicators 
(including syringe availability)
•	Harm-reduction indicators available  
(to be used for reporting and situation 
assessment)
 
II.3.3. Prevention 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.3.3.1. Support the development and 
implementation of good practice,  
guidelines and quality standards in the 
area of prevention
II.3.3.1.1. Update EDDRA (Exchange on drug 
demand reduction action) with prevention 
interventions data
•	 EDDRA updated, links with Best practice 
portal included where useful
II.3.3.1.2. Update the EIB (Evaluation  
instruments bank) with evaluation instruments 
data
•	 EIB updated
II.3.3.1.3. Refine the indicators, explore  
summative scores by area
•	 Prevention profiles updated
II.3.3.2. Maintain close collaboration with 
prevention research actors to follow the 
development of evidence
II.3.3.2.1. Participate in the activities of the 
European Society for Prevention Research 
(EUSPR) and contribute to the monitoring of 
prevention science
•	 EMCDDA input (presentations,  
communications, etc.) provided to  
prevention research initiatives
B. New developmental areas
II.3.3.3. Improve information on indicated 
prevention, focusing on early intervention 
especially for alcohol and cannabis
II.3.3.3.1. Organise expert meeting on  
experiences and evidence of interventions 
and methodologies used (brief intervention 
and motivational interviewing) in the grey 
zone between prevention and treatment
•	 Expert meeting organised and  
supporting documents available
II.3.3.4. Improve the existing information 
on prevention services for minorities (to 
support action 20 of the EU action plan)
II.3.3.4.1. Map and describe existing  
prevention services for ethnic minorities
•	 Project report prepared
•	 Technical report prepared
II.3.3.5. Present new methods in analysing 
and evaluating prevention interventions
II.3.3.5.1. Simplify and explain methods and 
outcomes of compared analysis and  
evaluation of prevention interventions in  
different contexts
•	 Thematic paper prepared
II.3.3.6. Develop and implement data  
collection tools in the area of  
environmental prevention strategies,  
especially concerning alcohol
II.3.3.6.1. Develop methods and protocols 
(in close partnership with DG SANCO) to 
systematically collect and classify information 
on environmental prevention policies
•	 Expanded set of indicators on  
population-based prevention approaches
•	Best practice portal section on  
environmental prevention developed
 
II.3.4. Good practice, guidelines and quality standards 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.3.4.1. Further develop the Best practice 
portal (BPP) supporting evidence-based 
interventions
II.3.4.1.1. Maintain and permanently update 
the BPP and increase quality of the web 
interface
•	BPP updated and user-friendly
II.3.4.1.2. Conduct systematic reviews of  
evidence to support improvement of the 
content
•	Synthesis of Cochrane reviews published 
on the BPP
II.3.4.1.3. Conduct a review to identify gaps 
in the research supporting evidence-based 
interventions
•	 Research gaps identified and presented on 
the BPP
B. New developmental areas
II.3.4.2. Improve understanding of  
pregnancy and substance use in Europe
II.3.4.2.1. Develop EU guidelines on  
pregnancy and substance use in collaboration 
with WHO
•	Guidelines prepared, to be published in 
2013
II.3.4.3. Further develop the  
contribution of the Reitox NFPs to  
information collection on and  
dissemination of good practices
II.3.4.3.1. Organise a special workshop on 
good practice during the ‘Reitox week’ (May 
2012)
•	Workshop organised and supporting  
documents available
II.3.4.3.2. Prepare the activity plan for 
2013–15
•	Activity plan 2013–15 adopted by Reitox 
NFPs
II. Monitoring and reporting on the drugs problem in Europe
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II.4. Supply and supply reduction interventions
Overview
The need to scale up the monitoring of illicit drug supply in Europe is an important component 
of the current EU action plan and the EMCDDA’s three-year work programme (2010–12). 
According to the strategy adopted during the first European conference on drug supply 
indicators co-organised by the European Commission and the EMCDDA (held in October 
2010), the overall conceptual framework to monitor illicit drug supply will integrate three 
components: drug markets, drug-related crime and drug supply reduction. Special attention 
will be given to the possible standardisation, extension and improvement of existing data-
collection systems and targeted research will be used to improve understanding of the 
topic. A roadmap (drafted in 2011) will comprise short-, medium- and long-term monitoring 
objectives for the three areas. 
 
In the area of drug markets, future activities will focus, among others, on improving drug 
price and purity data sets and exploring the potential of forensic science. The development  
of a European standard monitoring instrument on drug-law offences and of indicators on  
intra-European drug production will be key in the drug-related crime area, together with 
defining priorities for research. Policing and criminal justice agencies will play a central role 
in drug supply reduction. Work in this under-researched area will begin with a mapping 
exercise to provide an overview of drug supply reduction activities in Europe. 
 
The scoping and technical work started in 2010, in close cooperation with the European 
Commission, to develop the specifications for European key indicators in the area of drug 
supply (including supply reduction) will reach a final stage in 2012 with the joint organisation 
of the second European conference on supply indicators. This major event should allow 
a consensus to be reached at European level on the key indicators to be developed and 
implemented from 2013 in this domain. In addition in 2012, a substantial share of the 
EMCDDA’s resources in the area of drug supply and drug supply reduction will continue to be 
devoted to data collection and analysis of information in the fields of drug markets, crime and 
supply reduction. Furthermore, in the field of drug supply reduction activities, the pilot study 
launched in 2011 on European drug squads will be finalised. 
Specific objective Activities Expected outputs/results
A. Core activities
II.4.1. Step up data collection and  
analysis on crime, markets and supply 
reduction
II.4.1.1. Analyse drug production and  
trafficking trends in Europe: data collection 
and analysis, literature searches, contacts with 
external experts and international  
organisations, data extraction from national 
reports, analysis and drafting of final texts, 
production of figures
•	Analysis conducted and Annual report 
drafted
•	 Inputs provided for other products
II.4.1.2. Develop a technical framework and 
reconstruct historical data on drug tablets and 
on seizures in Europe
•	 Fonte database updated to include data on 
drug tablets and seizures
II.4.1.3. Prepare a report on ecstasy  
production, trafficking and markets in Europe: 
data collection and analysis, literature search, 
collaboration with Europol, coordination and 
editing of contributions, drafting of final texts 
•	 EMCDDA–Europol Joint publication  
published
II.4.1.4. Review working modalities and 
technical cooperation approach with Europol 
for the preparation of joint publications
•	New EMCDDA–Europol framework for  
preparation of joint publications is  
available
II.4.1.5. Complete the pilot study on drug 
squads in Europe: organisation of a technical 
meeting, complementary data collection, data 
analysis, drafting of report
•	Small technical meeting to review the 
results and the lessons learned from the  
implementation of the study 
•	 Technical report prepared 
II.4.1.6. Develop institutional coordination 
and data exchange with external partners on 
supply issues
•	Coordinated approach on supply issues 
with external partners: EC, Eurostat,  
Europol, Eurojust, Cepol, CoE/PG, 
UNODC, WCO, Interpol
B. New developmental areas
II.4.2. Develop key indicators on drug 
supply 
II.4.2.1. Organise 2nd European  
conference on supply indicators in  
collaboration with the European Commission: 
coordination with the EC, management of 
invitations and participants, organisation of 
the agenda and management of the  
speakers, organisation of logistics,  
preparation of supporting documents and 
follow-up (logistics, conclusions) 
•	2nd European conference on supply  
indicators organised, conclusions  
available 
II.4.2.2. Produce a strategy for the  
development of key indicators on drug supply 
•	 Internal working document prepared, with 
three main components: drug markets, 
drug-related crime, and drug supply  
reduction
II.4.2.3. Produce a roadmap for the  
implementation of the three key supply  
indicators
•	 Internal working document prepared  
comprising short-, medium- and long-term 
monitoring objectives for the three areas
II. Monitoring and reporting on the drugs problem in Europe
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II.5. Monitoring new trends and developments and assessing the risks 
of new substances
Overview
The EMCDDA has been assigned a key role in the detection and assessment of new 
drugs in the European Union under the terms of the Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new psychoactive substances. 
The Council Decision requires ongoing and dynamic work to ensure efficient information 
exchange. As in previous years, the EMCDDA will ensure the implementation of the  
early-warning system (EWS), together with Europol and its EWS partners in the Member 
States, the Reitox network. The EMCDDA database on new drugs (EDND) and the Drug 
profiles series will be further developed as a result of this dynamic work.  
 
In addition, and in view of the ongoing assessment of the Council Decision undertaken by 
the European Commission in the framework of the EU drugs action plan for 2009–12, the 
information exchange mechanism and the related data collection tools and guidelines will 
need to be adapted to the amended Council Decision or to the new legal instrument.  
If requested, support will be provided to the European Commission in the preparation of new 
legislation to replace Council Decision 2005/387/JHA. 
 
The EMCDDA in cooperation with the EMA will further operationalise the exchange of data 
available through the Reitox early-warning system and the EU Pharmacovigilance system, as 
set out in Article 28c of the new pharmacovigilance legislation. 
 
Methodological approaches to allow better identification and monitoring of new and 
established substances will be further developed through networking with forensic science 
centres or through new data sources. The potential of wastewater analysis — an emerging 
science — to monitor levels of illicit drug use in the community and to identify new drugs will 
be explored. Implementation of regular Internet snapshots will continue, with an improved 
methodology to provide a timely window on developments in monitoring new trends in new 
and established substances. A tool will be developed in the EDND to match ‘legal high’ 
products to substances. 
 
In consultation with the European Commission and in full compliance with EMCDDA mandate 
(1), the conceptual framework for monitoring the misuse of medicines will be finalised in 2012 
to support the implementation during the following years. 
(1) Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the European Monitoring Centre for Drugs and Drug 
Addiction (recast); REGULATION (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010; and Council Decision 2005/387/
JHA on the information exchange, risk-assessment and control of new psychoactive substances. 
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II.5.1. Implementation of the early-warning system 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.5.1.1. Implement the provisions of the  
information exchange phase of the  
Council Decision 2005/387/JHA 
II.5.1.1.1. Implement the information  
exchange mechanism, the early-warning 
system (EWS) 
•	 Timely notification of new psychoactive 
substances to the Member States, EC, 
Europol and EMA
•	Support (technical assistance, training,  
advice) provided to Member States, as 
needed
•	 Public health related warnings issued  
(if relevant) 
•	New substance profiles prepared for all  
notified substances
•	 European database on new drugs (EDND) 
regularly updated
II.5.1.1.2. Organise the Annual meeting of 
the Reitox EWS network 
•	Meeting organised and supporting  
documents available
II.5.1.1.3. Prepare the EMCDDA–Europol 
Joint report on a new psychoactive substance 
(if appropriate) 
•	 EMCDDA–Europol Joint report prepared 
II.5.1.1.4. Finalise publication ‘Profiles: 
national early-warning systems’  
•	 Publication of ‘Profiles: national  
early-warning systems’ 
II.5.1.1.5. Finalise the EMCDDA Monograph 
on new psychoactive substances
•	 EMCDDA Monograph published
II.5.1.2. Implement longer-term monitoring 
on new psychoactive substances
II.5.1.2.1. Collect and analyse EWS progress 
and final reports from the national EWS  
(Reitox) network of the Member States
•	60 EWS reports (30 mid-year/progress 
and 30 final reports) analysed and  
uploaded in the EDND
II.5.1.3. Ensure transparency in the 
implementation of the Council Decision 
2005/387/JHA
II.5.1.3.1. Prepare the EMCDDA–Europol 
Annual report on the implementation of the 
Council Decision, based on collection and 
analysis of the 2011 data (Article 10 report)
•	 EMCDDA–Europol Annual report on the 
implementation of the Council Decision 
published
II.5.1.4. Implement Article 28c of the 
Pharmacovigilance legislation
II.5.1.4.1. Finalise implementation  
arrangements with EMA and participate in 
training on the use of the EU  
Pharmacovigilance web-based information 
system (EudraVigilance)
•	 EMA–EMCDDA document on  
implementation arrangements available
•	 EMCDDA staff trained and information 
exchanged with EMA and the EU  
Pharmacovigilance system
II.5.1.4.2. Implement information exchange 
between EMCDDA and EMA on medicines 
and substances with medicinal properties
•	 EDND updated accordingly
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Specific objective Activities Expected outputs/results
II.5.1.5. Implement new data sources 
and strengthen further links with forensic 
science
II.5.1.5.1. Update all online drug profiles and 
prepare two new drug profiles (if appropriate)
•	Online drug profiles updated
•	Updated drug profiles published as a  
compendium
•	 Two new drug profiles published  
(if appropriate)
II.5.1.5.2. Strengthen the links and improve 
information exchange with the forensic  
science network 
•	 Forensic science network operationalised
•	 EMCDDA input at the Annual meeting  
of the European network of forensic  
science institutes
II.5.1.5.3. Adapt Internet monitoring  
methodology and conduct two Internet 
snapshots
•	Article submitted to scientific journal
•	 Two Internet snapshots conducted, data 
analysed and results presented in  
EMCDDA publications 
II.5.1.6. Implement risk assessment  
procedure in line with the provisions of 
Council Decision 2005/387/JHA in  
accordance with EMCDDA risk assessment 
guidelines (if requested by the Council)
II.5.1.6.1. Prepare and organise risk  
assessment exercise, including data collection 
and analysis, organising the Scientific  
Committee meeting and preparation of the 
report
•	 Risk assessment meeting of the Scientific  
Committee organised
•	 Risk assessment technical reports drafted
•	 Risk assessment report from the Scientific 
Committee sent to the Commission and the 
Council
•	New risk assessment guidelines further 
implemented
B. New developmental areas
II.5.1.7. Prepare the EWS to meet new 
legal requirements (if requested) 
II.5.1.7.1. Assist the Commission and the 
Council in preparing a new legislation to 
replace the Council Decision 2005/387/JHA 
•	Contribute to the preparation of new  
legislation to replace Council Decision 
2005/387/JHA (if requested)
II.5.1.7.2. Initiate the process to adapt the 
information exchange mechanism to the new 
legal requirements (if appropriate)
•	Draft conceptual framework for new EWS 
guidelines prepared
•	Structure of the EMCDDA–Europol Annual 
report and Reporting form on new  
psychoactive substances adapted 
•	Concept and structure of the new database 
prepared
II.5.1.8. Project Match: develop a tool 
in the EDND which matches ‘legal high’ 
products to substances
II.5.1.8.1. Compile data from various sources 
linking new drugs to substances
•	 Tabular format suitable for operational use 
prepared
II.5.1.9. Develop monitoring of the misuse 
of medicines (in the context of polydrug 
use)
II.5.1.9.1. Finalise the conceptual framework 
for monitoring misuse of medicines
•	Conceptual framework for monitoring 
misuse of medicines prepared
II. Monitoring and reporting on the drugs problem in Europe
Specific objective Activities Expected outputs/results
II.5.1.10. Further strengthen the EU 
actions and visibility in the field of new 
psychoactive substances  
II.5.1.10.1. Follow up and build on the results 
of the First international multidisciplinary 
forum on new drugs (EMCDDA, May 2011). 
Co-organise with ReDNet (EC-funded project) 
the European conference ‘Novel  
psychoactive compounds: the ever-changing 
world of psychoactive drugs’ (Budapest); and 
follow up on activities in partnership with 
NIDA
•	Conclusions and abstracts of conferences 
II.5.1.11. Initiate structured preparation of 
candidate countries, potential candidate 
countries and ENP countries for future 
participation in the EWS
II.5.1.11.1. Carry out training activities at 
national and regional level (if additional 
resources are available). Initiate Internet  
snapshot exercises on new drugs and ‘legal 
highs’, in cooperation with candidate  
countries, potential candidate countries, ENP 
and some non-EU countries (Ukraine, Russia)
•	 To be defined depending on resources  
available
 
II.5.2. Emerging trends 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.5.2.1. Increase capacity to monitor 
emerging trends
II.5.2.1.1. Assess the feasibility of relevant 
data collection on emerging trends and  
validity of existing indicators
•	 Internal working document prepared
II.5.2.1.2. Establish trend-spotting network •	 Trend-spotters meeting organised
•	Case study prepared
II.5.2.1.3. Develop a network of local,  
city-level monitoring
•	City network that helps assess emerging 
trends established
II.5.2.1.4. Further develop the rapid response 
team (RRT)
•	 EMCDDA rapid response team operational
•	 Rapid assessment on key issue(s)  
conducted
B. New developmental areas
II.5.2.2. Multidisciplinary project to assess 
and monitor illicit drugs in wastewater 
II.5.2.2.1. Follow-up of meetings and studies 
implemented in 2011
•	 Internal working document prepared
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II.6. Improving Europe’s capacity to monitor and evaluate policies
Overview 
 
An important aspect of the EMCDDA’s 2012 work programme is the scaling-up of 
activities that will improve Europe’s capacity to monitor and evaluate drug policies. Work 
in this area will be structured around three linked themes: the legal basis for drug policies 
and how laws are implemented; monitoring policy development and supporting policy 
evaluation; and understanding better the economic aspects of European drug policies. 
 
The analysis of laws and legal bases for interventions in European countries will focus 
on a comparison of penalties for trafficking, on different models and processes for 
alternatives to punishment and on comparing drug laws with the help of one or several 
indexes. 
 
In order to support the monitoring and evaluation of drugs strategies and action plans 
in the European Union a number of new products will be published in 2012, including 
the European guidelines for the evaluation of national drug strategies and action plans. 
Further work in this area will include the historical analysis of the content of EU drug 
policy documents and an inventory and comparison of international drug plans (EU, 
Americas, etc.). In addition, the EMCDDA will publish the first results of a mapping 
exercise on drug policy advocacy groups in Europe. 
 
In the area of public expenditure, the EMCDDA will develop national profiles that present 
available information on the topic, develop guidelines to estimate the costs linked with 
drug offenders in prison, and investigate the feasibility of estimating court costs related to 
drug-law offenders.
 
II.6.1. Laws and legal bases for interventions  
 
Specific objective Activities Expected outputs/results
A. Core activities
II.6.1.1. Increase analysis of national laws 
and legal bases for interventions  
and enhance their visibility
II.6.1.1.1. Organise the legal and policy  
correspondents meeting
•	 Legal and policy correspondents  
meeting organised and supporting  
documents available
II.6.1.1.2. Prepare a report on ‘Alternatives to 
punishment in practice: typologies,  
mechanisms, use and evaluation’ 
•	 EMCDDA Thematic paper drafted
II.6.1.1.3. Prepare a report on the range of 
penalties for comparable trafficking  
quantities, ‘Drug trafficking in Europe —  
How long for how much?’
•	 Technical report prepared
II.6.1.1.4. Finalise the index of drug laws for 
comparing EU Member States 
•	 Index finalised
•	 Technical report prepared
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II.6.2. Drug policy and support to the evaluation of the EU drug strategy and action plans 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.6.2.1. Examine specific drug policy 
models and better understand  
decision-making processes at the  
European, national and local levels
II.6.2.1.1. Develop at least one additional 
national drug policy profile 
•	National drug policy profile prepared
II.6.2.1.2. Assess and publish a study on drug 
policy advocacy groups in Europe
•	 EMCDDA Thematic paper published
II.6.2.1.3. Prepare an inventory and  
comparative analysis of international drug 
strategies (EU, OAS, etc.)
•	 EMCDDA Thematic paper published
II.6.2.2. Develop quality standards and 
guidelines in the drug policy evaluation 
field
II.6.2.2.1. Publish European guidelines for 
the evaluation of national drug strategies and 
action plans 
•	 EMCDDA Manual published
B. New developmental areas
II.6.2.1. Examine specific drug policy 
models and better understand decision-
making processes at the European, 
national and local level
II.6.2.1.4. Carry out preparatory work for the 
Selected issue on the drug policies of large 
European cities in conjunction with the Reitox 
network (2013 Selected issue)
•	 Preparatory work for the 2013 Selected 
issue carried out
II.6.2.3. Analyse changes in EU drug  
strategies and action plans 1990–2012
II.6.2.3.1. Prepare an analysis of the  
development of EU drug policy documents
•	 EMCDDA Thematic paper published
•	Database of coded information developed
 
II.6.3. Public expenditure and economic analysis 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.6.3.1. Improve the monitoring and  
reporting on drug-related public  
expenditure (based on the new model 
developed)
II.6.3.1.1. Publish national drug policy  
expenditure profiles on the EMCDDA website
•	Online national public expenditure profiles 
published
II.6.3.1.2. Develop methods to estimate public 
expenditure related to detainees for drug-law 
offences
•	 EMCDDA Thematic paper published
II.6.3.2. Further develop analysis of the 
impact of the economic recession and of 
austerity measures
II.6.3.2.1. Conduct an external study to 
prepare the 2013 Selected issue on austerity 
budgets and drug services (2013 Selected 
issue)
•	Study results available for the Selected 
issue
35
Work programme 2012
Specific objective Activities Expected outputs/results
A. Core activities
II.7.1.1. Coordinate scientific activities to 
ensure that resources are managed  
efficiently, that objectives are achieved 
and that quality control of outputs is  
assured
II.7.1.1.1. Organise regular Scientific 
coordination meetings and Scientific division 
meetings  
•	Scientific coordination meetings and 
Scientific division meetings organised and 
supporting documents available
•	 Improved internal coordination and  
planning, enhanced quality of outputs
II.7.1.1.2. Define and implement the  
EMCDDA scientific strategy 
•	Scientific strategy prepared 
II.7.1.1.3. Prepare the Selected issue on 
drugs and tourism
•	Selected issue published
II.7.1.2. Implement the conclusions of the 
systemic review of tools (SRT) resulting 
from the 2011 exercise
II.7.1.2.1. Set up the SRT implementation 
group and organise group meetings
•	SRT group set up, meetings organised and 
supporting documents available
II.7.1.2.2. Develop the strategic framework 
and the action plan for the implementation of 
the conclusions of the systemic review of tools
•	Strategic framework and action plan for 
implementation developed
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II.7. Scientific coordination, research and content support
II.7.1. Scientific coordination 
 
The scientific work of the agency covers a wide range of complex topics that require detailed 
knowledge and specialised expertise. Many of the EMCDDA’s outputs need these different 
topics to be brought together to produce issues-based analysis. Coordination of the scientific 
work programme is therefore an important task to ensure: the overall coherence of the 
work; that competing priorities are appropriately balanced; and that common technical and 
operational issues are addressed. The main activities planned for the Coordination team are 
the operational tasks required to ensure coordination of the scientific work although some 
transversal developmental tasks also need to be undertaken.  
 
A priority in 2012 will be to oversee and evaluate the work conducted in the cross-unit 
projects (CUPS). CUPs are timebound, formal structures tasked with completing important 
transversal tasks. In 2011, it was decided to continue the work of the treatment and prison 
CUPS.  
 
In 2012, the central task for each CUP is to develop a more integrated strategy to act as a 
springboard for launching activities in these areas in the 2013–15 work programme. In the 
area of treatment, the main task will be to develop a more unified strategy for data collection 
and analysis. In the prisons area, a consensus meeting will be organised and a new 
publication on drugs and prison will be released to provide a comprehensive overview of the 
current situation. The modelling CUP was not continued as it was decided, after evaluation 
and the structural changes within the agency, that it would be no longer useful. 
 
With respect to developmental tasks, the coordination team will play an important role in 
preparing the scientific aspects of the work to ensure that the EMCDDA is prepared for the 
technical challenges of the new three-year work programme. The systemic review process 
launched in 2011 will be concluded and some important methodological development tasks 
will be overseen. 
Specific objective Activities Expected outputs/results
II.7.1.2.3. Revise the structure, process and 
cycle for production and delivery of the 
national reporting package, in consultation 
with the NFPs
•	Guidelines for the new reporting package 
developed and presented for adoption by 
the NFPs
II.7.1.3. Enhance qualitative data  
collection and analysis
II.7.1.3.1. Develop and implement internal 
strategy for qualitative data collection and 
analysis
•	 Internal strategy for qualitative data  
collection and analysis developed
II.7.1.3.2. Collect, analyse and report for 
Voices paper on adolescent cannabis users
•	 EMCDDA Thematic paper published
II.7.1.4. Improve quality criteria for  
EMCDDA reporting tools
II.7.1.4.1. Review the use and potential of 
expert ratings on responses to drug use
•	 Technical paper prepared
B. New developmental areas
II.7.1.5. Ensure scientific coordination and 
improve understanding of specific areas 
under development 
II.7.1.5.1. Prepare a report on the  
relationship between drug use, impaired  
driving and traffic accidents 
•	 Technical report prepared
II.7.1.5.2. Develop an internal strategy on 
workplace drug testing, co-morbidity and 
other developmental areas 
•	 Internal working document prepared
•	Article on workplace drug testing submitted 
to scientific journal
II.7.1.6. Develop awareness on the ethical 
issues related to monitoring drug use and 
responses
II.7.1.6.1. Audit current debates and develop 
a conceptual framework for understanding 
debates on the ethical aspects related to 
monitoring drugs
•	 Literature review carried out and  
conceptual framework drafted
•	 Limited expert group meeting organised
 
II.7.2. Drug-related research and cooperation with the scientific community 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.7.2.1. Establish an overview of EU and 
national drug-related research 
II.7.2.1.1. Carry out ongoing information  
collection and analysis to update websites 
and drug-related research database
•	Dedicated websites (public, intranet and 
Scientific Committee extranet) updated, 
drug-related research database updated
II.7.2.2. Contribute to and coordinate 
EMCDDA contribution to relevant studies 
and research 
II.7.2.2.1. Support, as appropriate, and 
follow-up on and contribute to relevant studies 
and research, inline with the EMCDDA’s  
priorities and available resources  
(e.g. ERANID)
•	More efficient use of EMCDDA resources 
and more insight on research findings 
gained 
II.7.2.3. Sustain cooperation with  
addiction scientific journals to support 
increased visibility of the EMCDDA´s work
II.7.2.3.1. Organise the annual meeting of 
the International Society of Addiction Journal 
Editors (ISAJE)
•	 ISAJE annual meeting organised
B. New developmental areas
II.7.2.4. Promote and coordinate  
drug-related postgraduate academic  
training projects
II.7.2.4.1. Provide support to EC funding 
applications for ‘Initial training network on 
drugs’
•	 EC funded applications supported for  
establishing EU postgraduate ‘Initial  
training network on drugs’
II.7.2.5. Boost the exchange of  
information on research programmes and 
possible sources for funding within the 
Reitox network
II.7.2.5.1. Develop a ‘Research forum’  
module at the Reitox HNFPs meeting in May 
2012
•	 ‘Research forum’ module delivered at the 
Reitox HNFPs meeting in May 2012
II. Monitoring and reporting on the drugs problem in Europe
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II.7.3. Content support 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.7.3.1. Ensure the scientific coordination 
and editing of the 2012 Annual report
II.7.3.1.1. Carry out all activities related to 
the scientific coordination and editing of the 
2012 Annual report: planning and agreement 
on content, scientific writing, consultation with 
the NFPs, final draft and editing
•	Annual report 2012 prepared in line with 
the agreed timelines 
II.7.3.2. Ensure the preparation of the 
2013 Annual report 
II.7.3.2.1. Develop and implement a new 
concept for the EMCDDA’s Annual report
•	New concept and work processes for the 
Annual report developed
II.7.3.3. Coordinate the selection and 
drafting of guidelines for the 2014  
Selected issues
II.7.3.3.1. Prepare the guidelines for the 
2014 Selected issues
•	Guidelines adopted by the NFPs
 
II.7.4. Cross-unit projects 
 
II.7.4.1. Cross-unit project Treatment 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.7.4.1.1. Coordinate internal  
scientific exchange, critical assessment 
and coordination of the EMCDDA’s work 
in the treatment area
II.7.4.1.1.1. Organise regular meetings of 
staff involved in treatment data collection and 
analyses
•	CUP Treatment meetings organised and  
supporting documents available
II.7.4.1.2. Develop strategy for data 
collection and analyses on treatment and 
related areas
II.7.4.1.2.1. Prepare strategy based on the 
conceptual framework developed in 2011, in 
consultation with NFPs 
•	Strategy and action plan developed 
II.7.4.1.3. Implement the EMCDDA  
treatment data collection action plan
II.7.4.1.3.1. Prepare international thematic 
meeting on evaluation
•	 Preparatory work conducted
 
II.7.4.2. Cross-unit project Prison 
 
Specific objective Activities Expected outputs/results
A. Core activities
II.7.4.2.1. Coordinate the EMCDDA’s 
work on drugs and prison, including  
information on epidemiology and  
interventions, and report the results
II.7.4.2.1.1. Organise regular internal  
meetings and prepare working documents,  
as needed
•	CUP Prison meetings organised and  
supporting documents available 
II.7.4.2.1.2. Coordinate the preparation of 
the EMCDDA Selected issue (mandatory) on 
drugs and prison
•	Selected issue published
Work programme 2012
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Specific objective Activities Expected outputs/results
II.7.4.2.2. Develop a data collection  
strategy on drugs and prison at European 
level
II.7.4.2.2.1. Prepare the data collection  
strategy on drugs and prison based on  
contributions from different areas 
•	Data collection strategy on drugs and 
prison developed
II.7.4.2.2.2. Organise a European meeting 
on drugs and prison
•	Meeting organised and supporting  
documents available
II.7.4.2.3. Support and facilitate the 
exchange of information with European 
and international organisations on several 
projects (e.g. WHO) regarding drugs and 
prison
II.7.4.2.3.1. Participate in meetings, provide 
informal advice, exchange information, in 
particular with WHO Health in Prisons Project 
(HIPP), and with other international  
organisations
•	 EMCDDA input into international  
meetings (reflected by presentations,  
meeting reports, etc.)
II. Monitoring and reporting on the drugs problem in Europe
39
III
Section III 
Cooperation and collaboration with key external 
partners
Overview
The overall objectives for 2012 in this area are to further develop collaboration with the EU 
institutions and agencies, and to develop the services provided to the European Council, 
European Parliament and European Commission. Partnerships with international organisations 
will also be consolidated ensuring that their respective activities are complementary. 
Cooperation with non-EU countries will be developed with a focus on the added value of 
building national drugs observatories and monitoring systems with a European perspective. 
Attention will be paid to providing sound and consistent EMCDDA output in this area 
with efficient allocation of resources, and also to strengthening project management and 
monitoring of technical assistance projects. 
 
In the area of collaboration with EU institutions, the EMCDDA will contribute with technical 
information and drug-related data to different meetings and conferences organised by the 
Council and the EU Presidencies, the European Parliament and the European Commission. 
Systematic collaboration will ensure complementarity in EU-funded drug-related activities. 
In addition, the EMCDDA’s ongoing monitoring of the situation and responses at national 
and EU level will be used to assess the implementation of the political documents and to 
analyse the situation at the EU level. Thus, if requested by the EC, the EMCDDA will provide 
input to the monitoring process of the implementation of the EU drugs action plan and EU 
Communication and action plan to combat HIV/AIDS. 
 
Close collaboration will be continued with EU agencies based on the priority areas identified 
in existing agreements and work programmes. Examples include a joint publication with 
Europol on ecstasy production, trafficking and markets in Europe, and contribution to the 
ECDC report on monitoring the implementation of the Dublin Declaration. Cooperation with 
the EMA in implementing the pharmacovigilance legislation and with CEPOL in the training  
of police officers in Europe on drug-related issues will be further strengthened. 
 
With regard to international and regional organisations, exchange of expertise and data 
as well as contribution to technical meetings with UNODC, WHO and CICAD are planned 
with the objective of creating a better picture of the drug phenomenon at the European and 
global level and to develop harmonised drug monitoring systems. In the area of collaboration 
with candidate and potential candidate countries, the priorities for 2012 are: to continue 
preparing their participation in the EMCDDA through the new IPA–EMCDDA technical 
cooperation programme (IPA 4), to develop new capacity-building activities, to put the 
information collected into perspective and to provide targeted analysis to the EMCDDA’s  
key stakeholders. 
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Reitox activities include the organisation of the first ‘Reitox week’ in May 2012, the 
development of a Reitox Academy summer course on ‘European and national drugs 
observatories and monitoring’ (for July 2013), a Reitox Academy seminar on ‘the European 
Union, the EU drugs policy and the enlargement process under the Lisbon Treaty’ in 
December 2012, and the drafting of a Thematic paper on ‘1991–2011: challenges and 
perspectives for drug-related information in the Western Balkans’. 
 
Cooperation with the European Neighbourhood Policy (ENP) countries will see an important 
development in 2012 with the expected start of a first technical cooperation project. This 
project will include the countries that formally declare their interest to participate in the 
last quarter of 2011. This first activity will focus on building/strengthening national drug 
observatories and will include an in-depth analysis of the gaps and needs for information 
on the drugs situation in those countries so as to define a plan for future joint publications 
in 2013–15. Regarding cooperation with other non-EU countries, taking into account the 
limited resources available and as stressed in EMCDDA international cooperation strategic 
documents, activities will be limited to ad hoc and targeted support to EC-specific projects 
(upon the European Commission’s request) such as COPOLAD and CADAP. 
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 Specific objective Activities Expected outputs/results
A. Core activities
III.1.1. Support drug policy dialogue at 
EU level and ensure effective collaboration 
with the EU institutions and civil society
III.1.1.1. Provide expertise and technical 
information to the European Parliament,  
the European Council and the European  
Commission 
•	 Launch of the 2012 Annual report in the 
EU institutions organised
•	 EMCDDA contribution to the EU  
Presidencies events and technical  
documents provided
III.1.1.2. Participate and contribute with 
technical expertise to EU-level meetings such 
as: HDG, COSI, Inter-Service Steering Group 
(ISSG), political dialogues with third countries, 
as well as the EU participation in external 
fora 
•	 EMCDDA input to EU-level meetings,  
as reflected by presentations delivered,  
meeting minutes/reports and others
•	 EMCDDA input to the revision by the EC  
of the Framework Decision on drug  
trafficking (1)
•	 EMCDDA technical support provided to the 
Member States during the session of the 
Commission on Narcotic Drugs (CND) 
III.1.1.3. Provide support to civil society fora 
on drugs and HIV/AIDS-related issues 
•	 Presentations delivered
•	Contribution to documents and  
discussions
III.1.2. Increase and improve coordination 
and cooperation of the EMCDDA’s  
contribution to EC-funded drug-related 
projects
III.1.2.1. Systematic follow-up on EC-funded 
projects, ensuring synergies and timely  
contributions, in particular to relevant  
drug-related projects funded under DG 
Research, DG JUST, DG HOME and DG 
SANCO (EHEA) programmes
•	More systematic use of EMCDDA resources 
ensuring synergies and avoiding  
duplication of effort
III.1.3. Further develop technical  
cooperation on drug-related issues with EU 
agencies, such as Europol, ECDC, EMA, 
CEPOL and Eurojust
III.1.3.1. Implement existing agreements and 
work programmes and explore potential 
areas of work with other EU agencies such as 
EFSA and FRA 
•	 Existing agreements and work  
programmes implemented 
•	Analysis of potential areas of work  
performed and bilateral meetings  
organised, as appropriate
III.1.3.2. Contribute to collaborative meetings, 
specific projects, strategy documents and 
guidelines
•	 EMCDDA input, as reflected by  
presentations, meeting reports and other 
technical documents, provided
•	 Joint publications launched
•	 Joint analyses performed
(1)     Council Framework Decision 2004/757/JHA of 25 October 2004.
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III.1. EU institutions, agencies and civil society
III.2. Key external partners 
 
Specific objective Activities Expected outputs/results
A. Core activities
III.2.1. Exchange of knowledge and best 
practice in monitoring the drug situation 
with international and regional  
organisations active in the drugs field, 
such as UNODC, WHO, Council of 
Europe Pompidou Group, CICAD
III.2.1.1. Implement existing agreements and 
work programmes and continue exchange of 
expertise, know-how and information 
•	 Existing agreements and work programmes 
implemented
•	Contribution to specific projects and expert 
meetings provided
III.2.1.2. Contribute to developing data  
collection tools and building drug monitoring 
systems by promoting EMCDDA approaches 
and working methods at expert meetings and 
conferences 
•	 Participation in internal and external expert 
meetings, training activities and seminars 
assured 
•	 The EMCDDA handbook on building  
national drug observatories promoted and 
disseminated 
 
III.3. Candidate and potential candidate countries 
 
Specific objective Activities Expected outputs/results
A. Core activities
III.3.1. Prepare the candidate and  
potential candidate countries to the EU for 
their participation in the EMCDDA
III.3.1.1. Implement technical assistance  
activities to contribute to developing national 
data collection systems on drugs in line with 
EMCDDA standards and enhance the  
capacity of experts from the beneficiary  
countries to collect data in line with  
international standards (training activities, 
meetings, workshops, etc.)
•	Strengthened cooperation with IPA  
beneficiaries, to reinforce national capacity 
for data collection and reporting on drugs
•	 Training activities expert meetings, etc. 
organised
B. New developmental areas
III.3.2. Strengthen/develop the national 
expertise of candidate and potential 
candidate countries to monitor the drugs 
situation and to build national focal points 
III.3.2.1. Organise the first ‘Reitox week’ at 
the May HNFP meeting, where candidate and 
potential candidate countries participate in 
workshops and in training seminars
•	Candidate and potential candidate  
countries supported in their work at  
national level for developing NDO or NDIS
III.3.2.2. Carry out preparatory work for the 
organisation of a Reitox Academy summer 
school on ‘European and national drugs  
observatories and monitoring’ in Lisbon  
(to take place in 2013)
•	Comprehensive training programme and 
materials developed, full agenda prepared, 
experts/trainers identified and selected
III.3.3. Develop understanding of the role 
of EMCDDA within the broader context of 
the EU, the EU drugs policy and  
enlargement under the Lisbon Treaty
III.3.3.1. Organise a joint Reitox Academy 
seminar on ‘The European Union, the EU 
drugs policy and the enlargement process 
under the Lisbon Treaty’
•	Comprehensive training programme  
delivered and 2 experts per country  
(on average) trained
•	 Improved understanding by participants  
of the EU, EU drugs policy and the  
enlargement process
Work programme 2012
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Specific objective Activities Expected outputs/results
III.3.4. Provide EMCDDA stakeholders 
and audiences with a comprehensive  
overview of available information on the 
drugs situation in the Western Balkans
III.3.4.1. Develop a report ‘1991–2011: 
challenges and perspectives of drug-related 
information in the Western Balkans’
•	 Thematic paper prepared
III.3.4.2. Prepare first or improved national 
reports on the drugs situation in candidate 
and potential candidate countries
•	National reports prepared or improved, 
information on national situations updated, 
as available
 
III.4. European Neighbourhood Policy (ENP) countries and third countries 
 
Specific objective Activities Expected outputs/results
A. Core activities
III.4.1. Initiate structured cooperation with 
ENP countries to prepare their future  
participation in the EMCDDA Annual 
report 
III.4.1.1. Organise national scientific seminars 
with interested/committed partner countries 
with TAIEX support
•	 Two national scientific seminars with TAIEX 
support organised and supporting  
documents available
III.4.1.2. Start to implement a first technical 
cooperation project (start date depends on  
EC approval)
•	 First technical cooperation project started 
(kick-off meeting organised)
III.4.1.3. Organise a regional scientific  
seminar with Southern partnership countries 
as a follow-up to the Rabat seminar conducted 
in November 2010
•	 Regional scientific seminar with Southern  
partnership countries organised and  
supporting documents available
III.4.2. Promote EU know-how on regional 
and national drug monitoring systems and 
related observatories, as a contribution to 
EC policy instruments
III.4.2.1. Contribute on an ad hoc basis and 
upon request by EC to EC-funded programmes 
aimed at establishing national drug  
observatories and national drug monitoring 
systems (COPOLAD, CADAP)
•	 EC policy instruments supported by the 
EMCDDA’s know-how and standardised 
instruments and methodologies
•	 Two trainees representing national drug 
observatories from the CADAP  hosted by 
the EMCDDA (or A joint EMCDDA-CADAP 
traineeship programm for national drug 
monitoring experts from the CADAP  
countries implemented and assessed)
III. Cooperation and collaboration with key external partners
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IV
Section IV 
Supporting the achievement of results 
 
 
Overview 
 
The EMCDDA recognises that investing in data collection and analysis is only worthwhile if it 
results in useful products that can be accessed by those who need them in an appropriate form 
and timeframe. A range of communication activities support this aim and include: publications 
(printed and web-based), presentations, dissemination, media relations, public relations, events 
and marketing, and library services. The priorities for these areas are clearly set out in the 
2010–12 work programme. 
 
In the area of timeliness, the main challenge is to produce high-quality outputs to the agreed 
schedule. Improving workflows to ensure that outputs are processed efficiently with key quality 
controls respected will be a focus. The priority accorded to different products will be reviewed 
to ensure that work on labour-intensive products is not to the detriment of shorter more incisive 
ones. 
 
Using the appropriate medium for communicating with the various EMCDDA target audiences is 
essential and investment in pertinent and user-friendly web-based products will continue in line 
with technical developments and audience preferences. The organisation of the content on the 
public website will be fine-tuned to enhance its accessibility. 
 
The EMCDDA’s multilingual policy will be reviewed and a cost analysis performed to ensure 
that it is still meeting audience needs and still appropriate given the limited financial resources 
available. Guidelines for needs-based language provision will be drawn up to serve as a basis 
for making sound decisions in this area. The EMCDDA glossary project will continue with the 
identification and definition of further terms that pose a problem for translation. 
 
Communicating findings face-to-face — in the form of servicing visits from policymakers, making 
presentations at conferences and exhibitions and talking to the media — will remain a key 
channel for disseminating timely information to the audience in question. The EMCDDA will 
be represented at key events in the drugs calendar and its products disseminated at numerous 
meetings and conferences. 
 
Responding to differentiated needs remains a focus and tailored products for each EMCDDA 
audience have been conceived. A multimedia contract will facilitate the production of content 
in newer media forms, for example video content. Also, the EMCDDA’s use of social media to 
dialogue with specific audiences will be further developed and an e-mail version of Drugnet 
Europe introduced in response to audience demand. 
 
Further efforts will be made to obtain feedback on the impact of EMCDDA communication 
actions and the monitoring of web use, media coverage and distribution will be continued. A 
more comprehensive and structured monitoring and quantification of all EMCDDA activities that 
disseminate results and information will provide a sound basis for the effective management of 
communication resources.
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IV.1. Communicating the EMCDDA’s findings to external audiences
IV.1.1. Timeliness 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.1.1.1. Ensure the publication of  
high-quality and timely products in line 
with targets committed to in the 2010–12 
work programme
IV.1.1.1.1. Update and implement the  
EMCDDA communication strategy
•	Updated communication strategy and  
action plan aligned with outcome of  
systemic review
•	 EMCDDA work facilitated by improved  
internal communication
IV.1.1.1.2. Assure publication, launch and 
dissemination of outputs listed in the 2012 
outputs list
•	 Planned products published, launched and 
disseminated
IV.1.1.1.3. Improve quality control in the 
production process of EMCDDA products by 
formalising key-control and sign-off points in 
the workflows
•	Key quality control points identified and 
formalised 
IV.1.1.1.4. Hold regular Editorial board 
meetings involving key staff in the products 
production process to ensure tracking and 
quality control of outputs
•	 Editorial board meetings organised
•	 Improved planning for publication of 
products
IV.1.1.1.5. Complete the guidance documents 
and work processes used for the production of 
different outputs
•	Consolidated procedures (workflows, 
templates and guidelines) prepared and 
presented to EMCDDA staff
IV.1.1.1.6. Put in place additional framework 
contract(s) to support production of outputs 
(graphic design, editing, printing)
•	New framework contract in place, to  
improve flexibility/timeliness for contracting 
graphic design, editing and printing work
 
IV.1.2. Getting the medium right: accessibility, web-based products and language issues 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.1.2.1. Develop online tools in line with 
audience needs and developments  
in technology 
IV.1.2.1.1. Continue to improve the  
EMCDDA’s public website introducing new 
features
•	 Improved website with information more  
accessible to users
IV.1.2.1.2. Implement the outcome of the 
CMA (Content Management Application) 
road map project
•	New tool for web content management on 
the public website selected. New working 
procedures and workflows developed and 
implemented
IV.1.2.1.3. Implement a web governance 
strategy
•	 Policies, procedures and roles defined and 
documented
IV.1.2.1.4. Develop a policy and define a 
workflow for news publication across multiple 
platforms (social media, website, RSS feeds, 
etc.)
•	 Processes for news publication developed 
and implemented
IV.1.2.2. Assure better quality and  
relevance of multilingual products
IV.1.2.2.1. Continue to work with NFPs on the 
terminology/glossary project (as appropriate 
and in accordance with needs)
•	New terms with agreed and translated  
definitions uploaded to IATE (Inter Active 
Terminology for Europe)
Work programme 2012
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Specific objective Activities Expected outputs/results
B. New developmental areas
IV.1.2.3. Analyse current multilingual 
policy and publishing strategy 
IV.1.2.3.1. Review the agency’s products 
to identify what needs to be produced in 
what languages, taking on board the survey 
results from focal points and other feedback 
received. Establish a process for assessing 
whether a publication should be translated 
into a non-EU language
•	New multilingual policy prepared 
 
IV.1.3. Active communication: our participation 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.1.3.1. Enhance the EMCDDA’s  
reputation and recognition as the  
European central reference point in the 
drugs field 
IV.1.3.1.1. Further develop the training  
project ‘Representing the EMCDDA’ ,  
involving communication training activities for 
EMCDDA staff who go on mission (staff as 
ambassadors)
•	 EMCDDA staff provided with improved  
communication skills
IV.1.3.1.2. Launch Corporate Identity  
Phase II: 2012 project
•	Brand update in accordance with scope of 
refresh decided 
IV.1.3.1.3. Organise or participate at key 
annual events (Annual report launch, 26 June, 
promotional fairs, CND) and maximise  
exhibiting and other promotional  
opportunities (e.g. International days, key 
conferences)
•	 EMCDDA represented at key events
•	 Presentation folders, pictures, videos,  
media reports prepared (as appropriate)
IV.1.3.1.4. Build sound contacts and relations 
with journalists, provide media-friendly  
information with clearly defined messages, 
assess the impact via monitoring and press 
reviews and organise media training for 
EMCDDA staff 
•	 Interviews set up, catalogue of journalist 
groups further developed, support provided 
to NFPs to ensure optimal dissemination at 
national level
•	 Press conferences/press events organised 
•	 Press products (news releases, factsheets, 
etc.) prepared and released, ‘advanced 
warning’ techniques (e.g. via pre-tweets) 
improved and used more extensively
•	Media monitoring and evaluation (press 
reviews and analyses) 
•	 Training organised, staff provided with  
improved media communication skills
B. New developmental areas
IV.1.3.2. Develop the EMCDDA’s  
multimedia content
IV.1.3.2.1. Draw up guidelines and  
framework contract for developing multimedia 
content (e.g. video content for events and 
EMCDDA display areas)
•	 Framework contract launched 
•	Guidelines developed
IV.1.3.3. Develop material to support the 
EMCDDA’s representation work
IV.1.3.3.1 Draw up a framework contract 
to support the production of exhibition and 
promotional materials
•	 Framework contract launched
IV. Supporting the achievement of results
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IV.1.4. Disseminating and valorising our outputs 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.1.4.1. Optimise dissemination activities IV.1.4.1.1. Review dissemination channels 
and assess value and main target audience 
reached by each
•	 Improved understanding of the value and 
main target audience reached by current 
dissemination channels 
IV.1.4.1.2. Continue to analyse and reduce 
print-runs (and therefore costs) and replace 
them with the more flexible print-on-demand 
option offered by EU bookshop
•	 Reduced print-runs and new print-on-
demand system put in place 
IV.1.4.1.3. Ensure appropriate display of 
EMCDDA publications on EU bookshop and 
reinforce EU bookshop as the general public’s 
gateway to our publications
•	 EMCDDA products appropriately presented 
on EU bookshop 
B. New developmental areas
IV.1.4.2. Improve distribution of EMCDDA 
publications through developing e-mail 
subscription services 
IV.1.4.2.1. Send publications (in pdf format) 
on demand and produce e-mail newsletter
•	 E-mail subscription service set up
 
IV.1.5. Responding better to differentiated needs 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.1.5.1. Ensure that different target 
groups are reached with the most suitable 
channel/product
IV.1.5.1.1. Launch a survey to collect  
feedback from target user groups on  
relevance and importance of EMCDDA 
product(s) (starting with Drugs in focus)
•	 The results of the survey are analysed and 
a follow-up action plan developed
IV.1.5.1.2. Update scientific contacts and 
search for more websites and blogs which are 
relevant for reaching scientific audiences 
•	 Lists of scientific journal contacts expanded
•	 Relevant websites and blogs used for  
reaching scientific audiences identified 
IV.1.5.1.3. Work with scientific teams to 
identify key stakeholders in the practitioners’ 
group
•	Better targeted dissemination lists  
developed
IV.1.5.1.4. Regularly update the public  
website and launch awareness-raising 
products on international days to better serve 
citizens with drug-related information
•	 Publications, topic overviews to mark  
international days (Women’s, Children’s, 
World AIDS, Hepatitis, etc.)
•	Content provided to EU public health portal
B. New developmental areas
IV.1.5.2. Make the EMCDDA´s work  
available to new audiences
IV.1.5.2.1. Develop and organise the summer 
school ‘Drugs in Europe: supply, demand and 
public policies’
•	2012 summer school organised
Work programme 2012
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IV.1.6. Supporting scientific knowledge and research (library and documentation services) 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.1.6.1. Provide reliable and efficient 
information, library and documentation 
services supporting the research needs of 
scientific staff 
IV.1.6.1.1. Provide reliable and efficient  
information services, proactively  
disseminating information on a selective basis 
to support the research needs of scientific 
staff, and other information needs within the 
EMCDDA
•	 Information bulletins published at regular 
intervals
•	Ad hoc alerts distributed on an individual 
basis
•	 Literature searches
IV.1.6.1.2. Evaluate, acquire and manage 
information resources and maintain facilities 
conducive to study and research, suitably 
equipped for the organisation and utilisation 
of the library’s resources
•	A well-managed collection of electronic 
and print resources available 
•	 Fully equipped and furnished library
 
IV.1.6.1.3. Networking and cooperation with 
other libraries and librarians to exchange 
experience and share best practices
•	 EMCDDA input into Eurolib  
 
 
IV. Supporting the achievement of results
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Overview 
 
In the area of governance, the core objective will be to continue to ensure that the EMCDDA 
performs the tasks set out in its Regulation and the 2010–12 strategy in the most cost-effective 
way. As in previous years, continuous support will be provided to the Management Board in 
carrying out its mandate. This includes ongoing contact with the Board members, organisation 
of the statutory meetings and preparation of the documents to support their work. 2012 will 
also see the adoption by the Management Board of the agency’s new strategy and work 
programme for 2013–15. The document will identify the priority areas, goals and main 
objectives for the next three years and will set up an action plan for performing the activities 
and achieving the expected results. 
 
The EMCDDA’s Scientific Committee plays an important role in advising and assisting the 
agency on the scientific aspects of its activities. In 2012, the Scientific Committee will support 
the EMCDDA in the preparation of the 2013–15 three-year work programme and the 2013 
annual work programme, and will adopt a formal opinion on both documents. It will also 
contribute to the preparation of the Council’s annual dialogue on drug-related research. 
The Scientific Committee will be prepared to act under the ‘Council Decision on information 
exchange, risk-assessment and control of new psychoactive substances’, if requested by the 
Council, and to issue opinions on any scientific matters concerning the EMCDDA’s activity, at 
the request of the Director or the Management Board. 
 
The external evaluation of the EMCDDA, coordinated by the European Commission, is 
another important activity and the results available in 2012 will support the agency’s ongoing 
efforts to improve its work. 
 
At the operational level, the process of improving internal coordination of the EMCDDA´s 
work will continue. This involves organising regular Heads of unit meetings and ensuring 
follow-up on the decisions made, as well as refining the role and function of the Internal 
coordination group set up in 2011. 
 
At the same time, special consideration will be given to rationalising use of the agency’s 
resources and further improving its performance. To this end, a revision of internal processes 
will be conducted and proposals for improvement will be prepared. Furthermore, the role of 
planning, monitoring and reporting activities in supporting sound decision-making will be 
enhanced. New tools to collect information and document the work will be introduced and 
a system for performance monitoring will be gradually developed and tested, to be fully 
implemented during the next three-year strategy. 
 
The work of the Reitox coordination unit and of the Reitox network will focus on three main 
priorities and challenges: 1) providing support for the adoption and implementation of recent 
advances in the scientific work of the agency (new TDI protocol, updated definitions and PDU 
estimates, new framework for quality assurance and quality reports), 2) moving forward the 
implementation of the Reitox development strategy with a priority given to the added value 
of the work of NFPs at EU and national level through the launch of a ‘Reitox focus groups’ 
initiative, and 3) concluding the definition for a new structure and new working methods for 
Reitox NFP meetings and the organisation of the first ‘Reitox week’ in May 2012. 
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IV.2. Governance, management and networks
IV.2.1. Governance 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.2.1.1. Facilitate strategic  
decision-making process by providing  
support to the EMCDDA statutory bodies
IV.2.1.1.1. Coordinate, prepare and organise 
follow-up of the meetings and decisions of the 
Management Board, of the Executive  
Committee and the Budget Committee
•	 Two Management Board meetings, four  
Executive Committee meetings and four 
Budget Committee meetings organised and 
Board members provided with all the  
necessary documents to perform their 
duties
IV.2.1.1.2. Coordinate, prepare and organise 
the meetings of the Scientific Committee and 
follow up on the conclusions and  
recommendations 
•	 Two Scientific Committee meetings 
organised and members provided with all 
the necessary documents to perform their 
duties
B. New developmental areas
IV.2.1.2. Support the external evaluation 
of the EMCDDA
IV.2.1.2.1. Participate in the Steering  
Committee chaired by the EC and provide 
support and input to the external contractor, 
as appropriate (by means of participating in 
interviews, providing supporting documents 
and clarifications, and reviewing documents 
and reports produced by the external  
contractor) 
•	Quality input provided by the EMCDDA to 
support the external evaluation exercise
•	 Reports developed by the external  
contractor reviewed by the EMCDDA,  
in line with the terms of the contract
 
IV.2.2. Management 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.2.2.1. Implement effective management 
and sound decision-making processes to 
ensure achievement of results and efficient 
use of EMCDDA resources 
IV.2.2.1.1. Perform top-level managerial 
activities, organise regular Heads of unit and 
Coordination group meetings and implement 
the decisions made
•	Heads of unit meetings organised and  
decisions implemented
•	Coordination group meetings organised 
and recommendations followed up on
IV.2.2.1.2. Assess internal processes with 
a view to rationalising use of resources and 
improving performance
•	 Internal working group set up and proposal 
to rationalise use of resources and improve 
performance developed
IV.2.2.2. Ensure compliance with the data 
protection rules applicable to EU bodies, 
Regulation (EC) 45/2001
IV.2.2.2.1. Process all personal data in  
compliance with this legislation
•	Data protection rules applicable to EU  
bodies (Regulation (EC) 45/2001)  
observed in all EMCDDA activities
IV. Supporting the achievement of results
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Specific objective Activities Expected outputs/results
IV.2.2.3. Ensure effective collaboration 
with the Member States
IV.2.2.3.1. Conduct an assessment of the 
status of cooperation with the Member States 
to identify areas for further development
•	 Report on the status of cooperation with the 
Member States prepared
IV.2.2.3.2. Collaborate with the authorities in 
the host country, namely with the Parliament, 
Government, and Presidency of the  
Portuguese Republic
•	Contacts with the new persons in charge of 
drugs in the Portuguese Parliament,  
Government and Presidency of Republic 
duly established and operational
•	 Proposal to improve the usefulness/ 
visibility of the EMCDDA in Lisbon, namely 
with local authorities, prepared
IV.2.2.4. Strengthen the role of the  
EMCDDA in providing drug-related  
information to external partners
IV.2.2.4.1. Organise visits of external  
partners to the EMCDDA
•	Successful visits organised, through  
improved internal coordination and 
increased value for both visitors and the 
EMCDDA
 
IV.2.3. Strategic planning, monitoring and reporting 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.2.3.1. Ensure appropriate  
planning, monitoring and reporting of the 
EMCDDA´s activities
IV.2.3.1.1. Prepare the General report of 
activities 2011
•	General report of activities 2011 prepared 
and published online by 15 June 2012
IV.2.3.1.2. Develop the 2013–15 strategy 
and work programme
•	2013–15 strategy and work programme 
developed and adopted by the  
Management Board
IV.2.3.1.3. Prepare and conduct the 2012 
mid-year monitoring exercise
•	Mid-term monitoring report prepared
IV.2.3.1.4. Develop the 2013 Annual work 
programme
•	2013 Annual work programme developed 
and adopted by the Management Board
B. New developmental areas
IV.2.3.2. Improve performance  
monitoring, to facilitate sound decision 
making
IV.2.3.2.1. Develop performance indicators 
for the 2013–15 strategy and work  
programme
•	 Performance indicators defined, to be 
implemented within the 2013–15  
planning exercise
IV.2.3.3. Improve the collection,  
management and presentation of data 
related to EMCDDA events
IV.2.3.3.1. Implement the events management 
tool
•	 Events management tool fully operational
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IV.2.4. Internal control system and risk management 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.2.4.1. Ensure implementation of sound 
internal control system, in line with the 
existing EU regulations and practices 
IV.2.4.1.1. Verify thoroughly the financial 
transactions, notably as regards legality and 
regularity of operations, and provide  
recommendations on best practices, mainly 
concerning cost effectiveness of operations 
•	All financial operations submitted are duly 
verified ex ante and corrections entered 
where necessary
•	Measures for improvement of financial  
management taken, as appropriate 
B. New developmental areas
IV.2.4.1. Ensure implementation of sound 
internal control system, in line with the 
existing EU regulations and practices
IV.2.4.1. 2. Produce a repository of the state 
of compliance with the EMCDDA internal 
control standards for effective management 
and control 
•	 Repository prepared and updated every 
six months
 
IV.2.5. The Reitox network 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.2.5.1. Facilitate the decision-making 
process and encourage more involvement 
by the NFPs in content-related debates 
IV.2.5.1.1. Finalise the reorganisation of the 
Reitox HNFPs’ meetings on the basis of a 
clearer decision process and more  
involvement in content-oriented debates
•	Clearer and more efficient decision-making 
procedures for the Reitox HNFPs meetings 
prepared
•	 ‘Reitox week’ organised in May 2012 and 
supporting documents available 
•	New formula for the HNFPs meetings 
adopted by 30 September 
IV.2.5.2. Ensure strong and high-quality 
financial and administrative management 
of the grant agreements, making full use of 
the new dedicated management  
information system (HERMES)
IV.2.5.2.1. Implement HERMES (for the first 
full year) for financial and administrative 
management of the grant agreements
•	Main steps in grant management  
process fully documented, closely  
monitored and implemented without delays 
at the EMCDDA
IV.2.5.3. Maintain a very good level of 
operational execution of the grant  
agreements
IV.2.5.3.1. Monitor difficulties or delays in the 
management of the grant agreements and  
carry out on-site regular visits to the  
concerned NFPs for additional support and 
periodical external audits
•	 List of countries and interventions  
permanently updated and regular on-site 
checks and capacity-building activities 
implemented
IV.2.5.4. Provide tailored support to focal 
points in need of institutional, scientific or 
administrative support
IV.2.5.4.1. Provide on-site institutional support 
(upon request) and improve the follow-up of 
recommendations made in the quality reports
•	 Reitox NFPs are supported and are given 
more institutional visibility at national level
•	Better and more systematic follow-up  
of quality reports
IV.2.5.4.2. Support national activities aimed 
at establishing or strengthening a national 
drug observatory (NDOs), based on the 
Handbook on building NDOs and  
development of specific training materials
•	 Training and institutional activities  
promoting the role of NDO and new  
standard training materials available
IV. Supporting the achievement of results
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Specific objective Activities Expected outputs/results
IV.2.5.4.3. Update and implement a joint 
Reitox Academy work programme,  
including organising national or clustered 
Reitox Academies to help improve scientific 
quality (where relevant), and prepare the 
outline of the Reitox Academy programme 
2013–15
•	Updated Reitox Academy programme for 
2012, following the conclusions of the 
Reitox HNFP meeting of November 2011
•	 Tailored training provided on scientific or 
administrative topics and supporting  
documents available
•	Outline of the Reitox Academy programme 
2013–15 prepared 
IV.2.5.5. Give more visibility to Reitox  
developments at European and national 
level
IV.2.5.5.1. Disseminate the leaflet ‘Frequently 
asked questions about the Reitox network’, 
publish articles in relevant publications  
(Drugnet Europe), support national launches 
of the EMCDDA’s Annual report
•	 Information on Reitox network disseminated 
at main drug-related events
•	 Increased visibility of Reitox and EMCDDA 
work
B. New developmental areas
IV.2.5.6. Encourage and support the NFPs 
to develop partnerships and build new 
projects and activities
IV.2.5.6.1. Organise permanent working 
groups at the Reitox HFPs May meeting  
(Reitox week) with the aim of sharing  
experiences and developing partnerships
•	3 working groups organised during the  
Reitox week: ‘Added-value actions’,  
‘Project factory’ and ‘Research forum’
IV.2.5.6.2. Participation of NFPs in the  
development and activities of the Reitox 
coaching model
•	 Reitox coaching model activities  
organised with candidate countries,  
potential candidate countries, ENP  
countries and third countries
IV.2.5.7. Launch a pilot project of Reitox 
focus groups in all EU Member States, 
with the aim of exploring the information 
needs of professionals working in the field 
of demand reduction, and their  
expectations towards their NFPs and the 
EMCDDA
IV.2.5.7.1. Develop the proposal for the NFPs •	 Proposal for ‘Reitox focus group’ project 
developed
IV.2.5.7.2. Select the NFPs to participate in 
the ‘Reitox focus group’ project (7 for  
treatment, 7 for harm reduction, 7 for  
prevention, 7 for social reintegration), provide 
training and present the guidelines at the 
HNFPs meeting in May 2012
•	 List of participating countries and focus 
groups planning prepared
•	 Training delivered and guidelines available
IV.2.5.7.3. Conduct the focus groups in the 
countries and prepare the reports
•	28 Reitox focus groups reports prepared
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Overview 
 
In 2012, the activities in the area of Administration and supporting core business will focus 
on consolidating ongoing work and further developing the initiatives started in previous 
years. An underlying key issue will be the need to seek further optimisation of the resources, 
including through development and use of new IT tools and solutions.  
 
In the area of human resources, developing and implementing policies and procedures will 
continue, by making full use of the newly developed E-recruitment tool and the HR database. 
Furthermore, recruitment criteria and career development paths will be better defined for the 
different categories of jobs, which will contribute to enhancing the potential, satisfaction and 
motivation of EMCDDA staff. 
 
Improving the management of financial resources and enhancing effectiveness and efficiency 
in the execution of the EMCDDA budget will remain one of the key priorities of the agency 
in 2012. In this context, special attention will be paid to improving the planning and 
monitoring of the procurement operations necessary for the implementation of the annual 
work programme. Also, as part of the efforts to rationalise use of resources, activity-based 
management (ABM) and activity-based budgeting (ABB) will be further developed. This will 
include developing the existing ABM/ABB and cost-based accounting system and tools, 
further aligning the cost centres with the objectives and activities in the work programme, 
as well as further developing coordination between the financial and operational actors 
involved. 
 
In the area of infrastructure and logistics, ensuring a healthy working environment and 
reducing utility costs by optimising the use of space and functioning of existing facilities 
will continue to be given special attention. One developmental area is the Environmental 
Management System (SEM) that aims to promote measures and policies for environmental 
protection within the agency. 
 
The EMCDDA will continue cooperation with other EU agencies on administrative matters. 
This will include, among others, contributing to the preparation of the agencies’ input to the 
forthcoming reform of the Staff regulations.
IV. Supporting the achievement of results
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IV.3. Administration and supporting core business
IV.3.1. Human resources 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.3.1.1. Further develop, implement and 
monitor the policies, procedures and tools 
for the human resources (HR)  
management, to maximise potential,  
satisfaction and motivation of EMCDDA 
staff 
IV.3.1.1.1. Develop and apply structured 
and effective HR policies and implement the 
updated EMCDDA Staff policy plan 
•	 Retention of qualified staff and increased 
staff satisfaction
•	 Transparent internal HR procedures  
developed and implemented
IV.3.1.1.2. Apply efficient recruitment 
procedures (by fully using E-recruitment) and 
coherent career management measures 
•	 Fully operational and motivated staff 
IV.3.1.1.3. Carry out overall administration of 
personnel rights, entitlements and obligations 
by fully using and improving the HR database 
•	HR database operational and further  
developed, including two new modules: 
staff assessment and flexi-time registration 
IV.3.1.1.4. Provide relevant training  
programmes to support the needs for  
competency development of EMCDDA staff 
•	 Training programmes developed and  
implemented
•	 Increased staff capacity and skills 
IV.3.1.1.5. Further develop and implement the 
project ‘job families at the EMCDDA’ , started 
in 2011
•	 Recruitment criteria and career  
development paths better defined for the 
different categories (‘families’) of jobs
IV.3.1.2. Contribute to the exercise to 
reform the Staff regulations
IV.3.1.2.1. Provide concrete input to the 
coordination of the EU agencies to improve 
and simplify the Staff regulations
•	 EMCDDA input to the reform exercise
 
IV.3.2. Financial management 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.3.2.1. Ensure efficient and effective 
budget implementation 
IV.3.2.1.1. Assess and analyse the internal 
control systems 
•	 Improved procedures, financial  
management and budget execution
IV.3.2.1.2. Assess the procurement and  
contracting processes, with special focus on 
planning and monitoring of procurements, 
further develop access to EC framework  
contracts and improve reporting tools  
•	More efficient procurement processes and 
budget execution
•	ABAC contracts tool improved, to support 
the follow-up of the running contracts 
IV.3.2.1.3. Revise the existing financial  
reports and develop new reports in  
accordance with ABM/ABB and cost-based 
accounting system  
•	 Improved reporting tools, to further meet 
the needs of target users
IV. 3.2.1.4. Develop an ICT-based tool for the 
management of missions, to rationalise the  
related processes and further reduce  
timeframe for payments
•	 ICT tool for the management of missions 
developed, to be fully implemented  
in 2013 
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IV.3.3. Budget and accounting (including budget planning, monitoring and reporting) 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.3.3.1. Ensure effective budget planning 
and management
IV.3.3.1.1. Carry out timely and effective 
preparation of the EMCDDA 2013 draft 
budget and the 2014 preliminary draft  
budget and execution of the operations 
required for budget management 
•	 Required instruments and operations  
successfully prepared and executed
IV.3.3.1.2. Conduct regular monitoring, 
reconciliation and reporting of SAP CO with 
ABAC  
•	New SAP cost-based accounting system 
consolidated and fully implemented
IV.3.3.1.3. Develop new analytical financial 
reports  
•	New analytical financial reports  
developed, to provide a better overview of 
budget executions
 
IV.3.4. Infrastructure and logistics 
 
Specific objective Activities Expected outputs/results
A. Core activities
IV.3.4.1. Ensure safety at work, sound 
environmental management and security 
in the buildings, including reducing utility 
costs and promoting use of renewable 
energy
IV.3.4.1.1. Implement the necessary measures 
to ensure staff knowledge on and awareness 
of the evacuation procedures
•	Wardens trained 
•	 In case of an evacuation exercise, all staff 
evacuated within less than 16 minutes
IV.3.4.1.2. Review and implement security 
rules and procedures
•	Security rule book revised
•	Annual security risk assessment revised and 
action plan implemented
IV.3.4.1.3. Implement appropriate measures, 
including optimising control settings and  
separating circuits, to reduce utility costs
•	5% reduction of utility costs in comparison 
to the 2010 benchmark
IV.3.4.1.4. Promote and develop an  
Environmental Management System (SEM) 
in the agency
•	SEM developed and endorsed internally
IV.3.4.1.5. Organise the Greening network 
meeting in 2012
•	Meeting organised and supporting  
documents available
•	 Increased visibility and reputation of the 
EMCDDA in the greening network 
IV.3.4.2. Provide a suitable work  
environment and related services, 
and improve efficiency and effectiveness 
through promoting a customer-oriented 
approach
IV.3.4.2.1. Implement all necessary measures 
to ensure a healthy working environment
•	Health and safety risks identified and  
addressed
IV.3.4.2.2. Provide timely logistics services to 
address the requests made by the staff via the 
intranet support application
•	All requests for logistics support addressed 
in a timely and efficient manner 
IV.3.4.2.3. Review the EMCDDA Business 
Continuity Plan (BCP) requirements and 
develop the implementation plan   
•	BCP implementation plan developed 
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IV.3.5.  ICT  
 
Overview 
 
In the area of Information and Communication Technology (ICT), work will continue on 
developing the services and infrastructure necessary to support the activities of the EMCDDA, 
including data collection and analysis (e.g. Fonte, Drugs data analytical database, 
quantitative and qualitative analytical support applications), results dissemination (e.g. CMA, 
architecture of the Internet-facing systems), administrative support systems, grants management 
system, network and internal systems architecture review. 
 
The development and further maintenance of information technology solutions and tools is 
one of the ICT areas that contributes most to rationalising work processes and optimising 
EMCDDA resources. Some important projects are planned in 2012, including the inception 
phase of a future mission management application, as well as the full implementation of the 
events management application. 
 
Furthermore, the approach to developing application and service roadmaps will be continued 
and strengthened. This involves establishing clear roadmaps for services and applications in 
production, as well as the underlying supporting infrastructure. This will improve forecasts and 
multi-year investment planning. 
 
Another initiative for 2012 will be the analysis of the historical consumption trends in the 
ICT area. This will allow better estimation of needs and will contribute to possible savings 
and further reduction in the utilisation of resources. This theme spans core activities and new 
development areas alike, and binds together continuity and planned development of the basic 
ICT infrastructure and support services with the activities needed to support the EMCDDA’s 
pillar work processes including data collection, data analysis and the development and 
dissemination of EMCDDA products, or the establishment of a new service following business 
needs. It follows the example of the Commission-wide IT-Governance initiative and is further 
fuelled by the IAS recommendations following the IT risk self-assessment and maturity self 
evaluation conducted at the EMCDDA. 
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Specific objective Activities Expected outputs/results
A. Core activities
IV.3.5.1. Improve the reliability and 
quality of the services provided and their 
implementation guidelines
IV.3.5.1.1. Carry out the necessary  
activities to ensure infrastructure management 
and evolution
•	 Planned replacement of infrastructure  
(servers and laptops) implemented
•	User desktops operating system, Windows 
7, migration prepared and initiated
•	Back-up service upgrade (first phase)  
implemented
IV.3.5.1.2. Implement the actions needed to 
ensure the running status and the operational 
maintenance of all ICT services in production 
(business continuity) 
•	Continued ICT operational services  
availability management
•	Software licenses maintenance
•	Hardware maintenance and support
IV.3.5.1.3. Further define and optimise the 
services and related procedures
•	Services and related procedures,  
standards, roles and costs, definitions 
further developed
IV.3.5.2. Introduce and apply best 
practices and standards of governance, 
planning and service management
IV.3.5.2.1. Refine the procedures and  
processes related to activities and budget 
planning and management, and make use of 
the established project evaluation matrix to 
track project planning and execution
•	 Project evaluation matrix further refined 
and developed, to track project  
planning and execution, leading to  
improved planning and monitoring of the 
ICT work programme
IV.3.5.2.2. Further develop the project and 
project portfolio management approach for 
the planning, prioritisation and follow-up of 
projects and activities in their relation to the 
ICT work programme
•	 Improved planning and monitoring of the 
ICT work programme
IV.3.5.2.3. Implement the action plans arising 
from the findings of the IAS-promoted ICT risk 
self-assessment and Fonte security audit
•	Action plans implemented
IV.3.5.3. Develop and maintain ICT  
solutions and tools to support the  
EMCDDA’s work and contribute to efficient 
use of resources
IV.3.5.3.1. Carry out preparatory activities 
for the development and implementation of 
roadmaps for data collection and analysis
•	 Preparatory work for the implementation of 
Fonte II carried out
•	Study to support Analytical database  
development roadmap concluded
IV.3.5.3.2. Provide support and regular  
maintenance services, implementation of 
upgrades related to the annual cycle of drugs 
data collection, web content management 
operational services and maintenance (CMA, 
web content management application)
•	 Fonte fully operational for 2012 data  
collection run
•	 Ensure required CMA updates and  
operational status
IV.3.5.3.3. Contribute to the finalisation of a 
CMA roadmap and its implementation
•	CMA roadmap approved and 2012 
planned actions concluded
IV.3.5.3.4. Develop and provide support for 
the implementation of ICT solutions meeting 
established business requirements, such as the 
Mission management tool, the Events  
management tool and the Document  
management tool  
•	 Internet monitoring project support
•	 Events management application  
operational
•	Mission management application  
inception and analysis phases concluded
•	Document management programme 
launched. 2012 planned projects  
concluded 
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Annexes
Risk factors identified for delivery of the 
2012 work programme
Likelihood of risk and respective impact on the 2012 work programme
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1. Substantial change in the current  
financial perspectives for the EMCDDA 
budget relying on the EC grant. 
The 2012 work programme has been drawn up on the basis of the EMCDDA’s 
draft budget for 2012 which relies on EC funding of EUR 15 550 920.  
Any reduction in this sum could require outputs to be reviewed.
2. Supplementary specific requests from 
EU institutions to provide technical support 
for the implementation of EC programmes 
and actions.
An extensive number of core tasks in support of the EU institutions  
(contribution to the EU drugs strategy and action plan, implementation of the 
Council Decision on new drugs, support to the second progress report for  
implementing the Council Recommendation of 18.6.2003, support to drug 
policy dialogue at the EU level by providing expertise and technical  
information to the European Parliament, the Council and the European  
Commission, amongst others) have been foreseen for 2012.  
However, additional requests from EU institutions to provide technical  
support for implementing actions and programmes would require priorities to 
be reviewed (1) and supplementary resources to be identified. Concerning, in 
particular, the implementation of the Council Decision on new psychoactive 
substances, and in view of the high number of new substances (notably ‘legal 
highs’) appearing over a short time period, a significant risk exists that multiple 
risk-assessment exercises will be required on these substances, which would 
pose an additional burden on the work programme and budget resources  
available. 
3. Supplementary requests from Member 
States and third parties to provide  
expertise in specific domains.
The current level of requests can be accommodated in routine work, but a 
significant increase in demand for this type of expertise would need additional 
scientific resources dedicated to it and would need to be balanced against 
other priorities of the work programme (1).
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During 2011, and in line with the approach already followed throughout 2010, the EMCDDA 
has, in the framework of a more systematic risk identification and assessment exercise, identified 
potential risk factors that could affect its planned deliveries. That initiative has led to the setting 
up by the end of 2010 of a fully-fledged central Risk Register, which benefited from successive 
updates since then. The table below is based on that Register; it lists the main potential risks 
that could negatively impact on the expected outputs and compliance with objectives of the 
EMCDDA. A brief assessment of the likelihood of occurrence and of the potential impact of 
the risks identified is provided. Where applicable a summary of the main mitigating measures 
already taken and planned in order to tackle risks identified is also provided.
Annex I 
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Risk factors identified for delivery of the 
2012 work programme
Likelihood of risk and respective impact on the 2012 work programme
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4. Lack of proper funding for NFPs in the 
Member States, which might negatively 
impact their capacity to properly comply 
with reporting obligations towards the 
EMCDDA. This risk could be compounded 
by an insufficient funding of information 
collection in Member States as a whole, 
which in itself would curtail the NFP  
capability to provide reliable information 
to the EMCDDA.
All core monitoring activities could be affected, notably the review of  
developments in drug use and responses in Europe. Monitoring of  
epidemiology by key indicators and of responses and interventions applied in 
respect of drug-related problems would also be affected.  
 
However, the high political visibility of the drug phenomenon renders sizeable 
and widespread cuts in NFP financing unlikely and acts as a mitigating risk 
factor. Under unfavourable scenarios, priorities assigned to the NFP affected 
would have to be reviewed, in order to ensure availability of core information. 
Commissioning by the EMCDDA of tasks to NFP staff could also be envisaged 
as a mitigating measure should the necessary appropriations be available in 
the EMCDDA budget.
5. Unauthorised use or misuse of EMCDDA 
products by external parties, notably for 
commercial or profit-making activities. 
Such abuses might entail reputation risks 
to the agency, notably if the contents of the 
original publications were to be modified, 
rendered incomplete or inaccurate and the 
EMCDDA be cited as the editorial source.
This risk materialised at the beginning of 2011, in that the copyrights of a 
number of EMCDDA publications have been violated. Although there is so far 
no evidence that the contents of its outputs have been substantially changed, 
the reputation risk remains since the agency does not have any control on the 
quality of products identifying it as the editor and sold illegally by a private 
company. 
Since this practice has affected a wide range of EU institutions and agencies, 
the EC Publications Office has requested the publisher in question to stop it. 
In case this situation were to persist, the possibility of setting up controls to the 
downloading of our external products ought to be assessed, keeping however 
in mind that they should be made available to audiences as broad as possible.
6. Natural catastrophes: earthquakes  
(leading to possible tsunamis) or floods
The location of the EMCDDA facilities, bordering the Tagus river, raises a  
potential risk of being affected by any of these natural catastrophes. 
 
The likely consequences of a major earthquake are hardly predictable and  
appropriate measures would have to be taken in order to deal with the  
resulting damages. The EMCDDA is presently located in an area of seismic 
activity. The likelihood of a tsunami comparable to the one that destroyed  
downtown Lisbon 255 years ago can be considered as very low, since it is 
clearly a rare phenomenon. A landslide of the building caused by earthquakes, 
although not very likely, cannot be ruled out. 
 
As regards Tagus flooding, some information available (notably a report issued 
by Unisys in 2008) leads us to believe that the potential risk here is low.  
On the other hand, it is conceivable that a combination of heavy rain with 
Tagus high tides could cause flooding of the underground car park. Further  
mitigating measures to deal with this risk ought to be agreed with and taken by 
the Administration of the Port of Lisbon (APL), the entity that owns the Cais do 
Sodré building. A letter in this sense was sent to APL in November 2010. 
 
Furthermore, a very comprehensive insurance contract covering ‘inter alia’ 
adverse effects from earthquakes, landslides and floods has been signed and 
would provide financial compensation should these events materialise.
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Risk factors identified for delivery of the 
2012 work programme
Likelihood of risk and respective impact on the 2012 work programme
7. Terrorist attacks The new facilities, as they are more visible than before, could, at least in theory, 
attract the attention of terrorist groups. The likelihood of such an event is  
considered to be low, mainly because Portugal has no serious recent  
background of this kind of attack. Moreover, if the target of such actions were 
to be the EU institutions or the like, there are far more visible and emblematic 
institutions in Europe, a fact that should decrease the potential risk faced by the 
EMCDDA in this respect.
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8. Risks in the Information Technology (IT) 
area 
A risk management draft plan for the period 2011–12 has been proposed for 
comments and further approval.
In 2011, the specific risks already identified during 2010 in this area were 
subject to a new assessment, following adoption of a number of actions and 
mitigating measures; as a result of that assessment the situation regarding 
potential risks in the IT area for 2012 can be summarised as follows: 
 
Governance risks, notably linked to: a) suboptimal investment decisions in IT;  
b) the existence of certain weaknesses in the management of IT projects,  
notably due to a lack of a proper definition of IT needs; c) deployment in  
production of IT developments and applications not fully tested; and d) belated 
or unsatisfactory responses from IT services in cases of emergencies, mainly due 
to a lack of properly documented procedures.
Mitigating measures to deal with these risks have been implemented, of which 
the most important have been the following: a) setting up of a register with a 
categorisation of ICT investments; elaboration of a detailed ICT reporting of 
activities from 2010 and of a project catalogue for ICT; b) engagement of the 
EMCDDA in inter-institutional framework contracts, ensuring good quality and 
reliability of services at advantageous prices, and reducing red tape;  
c) enforcement of a separation between development and production systems  
environments, supported by an upgrade of corporate servers; and  
d) improvement of documentation of processes, leading to a number of best 
practice examples in the agency. The setting up of an environment for corporate 
database restores has also contributed to palliate adverse effects in cases of 
emergency.
A wide range of additional measures and actions is expected to reduce the 
existing risks to nearly tolerable levels no later than the end of 2012:  
a) implementation of a portfolio management approach, including listing of 
projects to be selected in view of the top priorities of the agency; b) further 
development of a ‘turn-key’ (rather than ‘man-days’) project approach;  
c) reinforcement of a now clear separation between development and  
production systems in IT, while seeking a stricter segregation of duties amongst 
staff operating in those environments; and d) better documentation of  
procedures, to be carried out under the programmes I–Assets 2010 and  
I–DeskM2009.
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Risk factors identified for delivery of the 
2012 work programme
Likelihood of risk and respective impact on the 2012 work programme
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Technical risks, notably linked to a) software configuration management  
problems resulting from not properly planned installations of software, coupled 
with the lack of fully developed configuration management procedures;  
b) inconsistent application of patching procedures, compounded by insufficient 
documentation of interventions and systems updates; and c) security violations, 
due to the lack of adequately documented procedures in the IT area. 
As a result of these weaknesses, negative effects on business continuity and 
recovery in case of events entailing loss of data and/or of operational capacity 
would probably ensue, as they have already materialised in the past. 
Although not yet fully sufficient in view of the agency’s needs, most relevant  
mitigating measures have already been implemented, such as: a) the setting up 
of an automatic monitoring system to deal with installed configurations,  
combined with audits of configurations of the principal business support 
systems; conception of a ‘documentation tree’ (draft document classification 
proposed and being reviewed for approval) as the basis for a future  
documentation set covering risk management, security and governance in IT;  
b) ‘ad hoc’ testing of potential consequences emerging from patching  
procedural weaknesses and systematic registration of interventions performed;  
c) hosting of the agency portal at an alternative site; procurement of specialised 
assistance services in cases of disaster and preparation of a plan for service 
continuity; and d) ad hoc analysis of potential security problems, audits on the  
configuration of application servers and acquisition of an additional safe box.
Furthermore, a comprehensive set of additional measures has been foreseen, 
it being expected that the existing risks in this field will be reduced to tolerable 
levels in 2012: a ‘Definitive Software Library’ is expected to be set up before 
the end of 2011; a first version of a Business Continuity Plan will be set up until 
the end of the first quarter of 2012; the implementation by the end of 2011 of 
the I–DeskM2009 programme will address most of the software  
configuration management issues; a proper definition of patching specific 
procedures is progressing as planned; contracting of external audits on areas 
deemed as particularly security sensitive, such as telecommunications.
9. Unexpected departure of key members 
of staff
Given the highly specialised and technical nature of much of the agency’s work, 
finding suitable replacements can be a time-consuming task. The EMCDDA’s 
2010 reorganisation of scientific units provides sounder back-up arrangements 
for all staff concerned, whilst allowing a wider decentralisation of  
responsibilities in this key area.  
 
Investment in human resources ensures that arising needs can be acted upon 
with minimum delay in most cases. 
 
Job profiles have been designed with a view to recruit staff for transversal tasks 
and facilitate sharing of knowledge and expertise within small working groups. 
Moreover, it has been planned to shorten the current delays for staff recruitment. 
 
A stable contracts policy with key staff, notably in scientific areas, has been 
pursued and ought to be reinforced.
(1) The process for reviewing priorities is as follows: identify projects/meetings/studies/recruitments that can be delayed, downsized or cancelled and reassign 
resources appropriately.
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Risk management
The worst case scenario would be linked to a major earthquake leading to a tsunami.  
As hinted above, an emergency/salvage plan conceived to address the resulting damages 
would be needed. Even so, disruption of the EMCDDA activities would probably ensue, the 
respective duration being dependent on the severity of the catastrophe and of the promptness 
of the aid received from public and/or private sources. 
 
It is to be noted that a very comprehensive insurance contract covering inter alia adverse 
effects arising from earthquakes, landslides, floods and terrorist attacks has been in force 
since 2010 and would provide the necessary financial compensation in case such events 
materialise. The responsibility for further measures aimed at mitigating the risk of floods at  
the building belongs to its owner, the APL, as stipulated under the leasing contract.  
 
Regarding specifically the IT area linked risks, the main consequences would be felt on 
business continuity and could also affect sound financial management, the latter to the extent 
that suboptimal investments in IT could occur, both in terms of purchases made and ‘value for 
money’ obtained thereby. To be noted, however, that the actions already taken coupled with 
those under implementation and planned are expected to bring these risks down to tolerable 
levels no later than 2012.  
 
Apart from the situations mentioned in the paragraphs above, the types of consequences that 
could arise from the listed risks would sequentially be:
a)   reduced activities in support of partners and for non-core tasks;
b) delay or postponement of necessary developmental work, support and capacity-building 
activities;
c) reduction in capacity for analytical work and transversal products;
d) reduction in the scope or quality of planned outputs.
Except for major catastrophes (notably tsunamis), should any of the above scenarios occur,  
a detailed assessment of their impact both in budgetary and operational terms would have to 
be conducted. The implications of this assessment would then need to be considered in terms 
of the overall priorities of the work programme.
In case of major catastrophes, further measures would of course be needed. 
 
The EMCDDA will use and further strengthen its internal monitoring and evaluation capacity 
to prevent, manage and minimise the impact of the above-mentioned risks. For this purpose, 
it has adopted a series of measures aimed at improving the planning, monitoring, assessment 
and execution of its work programme and budget.
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The amounts indicated in the table below are based on the EMCDDA’s budget for 2012 that 
the EMCDDA’s Management Board should adopt in December 2011. This budget relies on 
the following revenues:  
 
•			EUR	15	550	920	to	be	provided	by	the	EC	subsidy	to	the	EMCDDA; 
•			EUR	414	789	to	be	provided	by	Norway	for	its	participation	in	the	EMCDDA; 
•			EUR	50	000	to	be	provided	by	Turkey	for	its	first	year	of	participation	in	the	EMCDDA,	
by assuming that the relevant agreement will enter into force on 1 July 2012; 
•			EUR	50	000	to	be	provided	by	Croatia	for	its	first	year	of	participation	in	the	EMCDDA,	
by assuming that the relevant agreement will enter into force on 1 July 2012. 
 
Furthermore the EMCDDA’s 2012 budget enters as assigned appropriations a financing of 
EUR 350 000 from the IPA programme for the execution in 2012 of a project for technical 
assistance aimed at preparing IPA Beneficiaries for their participation in the EMCDDA  
(so called IPA 4 project – first year of execution). 
 
The tables below present the estimated allocation of the EMCDDA’s 2012 budget 
appropriations for the implementation of the EMCDDA’s 2012 work programme: 
 
A. Monitoring and reporting on the drugs problem in Europe (vertical 
operations) 
 
WP objectives and activities Main actors 
for implemen-
tation/ cost 
objects
Allocated human resources  (fte/year) (1) Allocated budget resources – Non assigned appropriations 
(EUR)
O TA CA SNE Total HR For direct cost of 
operations (2)
For indirect cost of 
operations (3)
Total budget
Data collection, analysis and  
quality assurance
EPI + RTX + IBS 0.5 2.2 3.5 0 6.2 564 099 460 514 1 024 613
Key indicators and monitoring the 
epidemiology of the drug situation
EPI 0.5 5 1.5 0 7 636 885 519 935 1 156 820
Monitoring demand reduction 
responses, interventions and 
solutions applied to drug-related 
problems
IBS 2 4.9 1 0 7.9 1 111 317 586 784  1 698 101
Supply and supply reduction 
interventions
SAT 0 2.5 0.5 1 4 373 562 297 106 670 668
Monitoring new trends and  
developments and assessing the 
risks of new substances
SAT 0 2.5 1.5 0 4 373 562 297 106 670 668
Improving Europe’s capacity to 
monitor and evaluate policies
POL 0 4 1 0 5 550 123 371 382 921 505
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Annex II 
Estimated allocation/use of the appropriations provided under the 
EMCDDA 2012 budget for the implementation of the EMCDDA 2012 
work programme
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WP objectives and activities Main actors 
for implemen-
tation/ cost 
objects
Allocated human resources  (fte/year) (1) Allocated budget resources – Non assigned appropriations 
(EUR)
O TA CA SNE Total HR For direct cost of 
operations (2)
For indirect cost of 
operations (3)
Total budget
Scientific coordination, research 
and content support
SDI + IBS + POL 1 4.5 0 0 5.5 643 057 408 520 1 051 577
Total 4 25.6 9 1 39.6 4 252 605 2 941 347 7 193 952
(1) Fte/year – full time equivalent per year; O – officials; TA – temporary agents; CA – contract agents; SNE – seconded national experts.
(2) Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP.
(3) Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA mission/task/WP, as their 
immediate aim is to support operational activities and staff. These overheads are distributed to operational activities in proportion of the human resources assigned for the implementation 
of these activities.
B. Cooperation and collaboration with key external partners (transversal operations) 
 
Objectives and activities Main actors 
for implemen-
tation/ cost 
objects
Allocated human resources  (fte/year) (1) Allocated budget resources – Non assigned appropriations 
(EUR)
O TA CA SNE Total 
HR
For direct cost 
of operations (2)
For indirect cost of 
operations (3)
Total budget
EU institutions, agencies and 
civil society
Directorate + 
SDI
0 1.5 0 0 1.5 117 530 111 414 228 944
Key external partners Directorate + 
RTX
0 0.6 0 0 0.6 52 530 44 566 97 096
Candidate and potential  
candidate countries
RTX 0.5 2.4 0.5 0 3.4 369 363 252 540 621 903European Neighbourhood 
Policy (ENP) countries and third 
countries
(1) Fte/year – full time equivalent per year; O – officials; TA – temporary agents; CA – contract agents; SNE – seconded national experts.
(2) Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP.
(3) Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA mission/task/WP, as their 
immediate aim is to support operational activities and staff. These overheads are distributed to operational activities in proportion of the human resources assigned for the implementation 
of these activities.
C. Supporting the achievement of results (transversal operations) 
 
Objectives and activities Main actors 
for implemen-
tation/ cost 
objects
Allocated human resources  (fte/year) (1) Allocated budget resources – Non assigned appropriations 
(EUR)
O TA CA SNE Total 
HR
For direct cost 
of operations (2)
For indirect cost of 
operations (3)
Total budget
Communicating the EMCDDA’s 
findings to external audiences 
(including translation)
COM 1 9 2 0 12 2 130 110 891 318 3 021 428
Governance, management and 
networks (executive and corpo-
rate management + Governing 
bodies’ activities)
Governing  
bodies +  
Directorate 
+ IBS
3 4.5 2 0 9.5 943 470 705 626 1 649 096
RTX + NFPs’ 
co-financed 
activities
0.5 1.4 1.5 0 3.4 3 000 751 252 539 3 253 290
Annex II. Estimated allocation/use of the appropriations
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Objectives and activities Main actors 
for implemen-
tation/ cost 
objects
Allocated human resources  (fte/year) (1) Allocated budget resources – Non assigned appropriations 
(EUR)
O TA CA SNE Total 
HR
For direct cost 
of operations (2)
For indirect cost of 
operations (3)
Total budget
Total 4.5 14.9 5.5 0 24.9 6 074 331 1 849 483 7 923 814
GRAND TOTAL FOR OPERATIONS (a + b) 9 45 15 1 70 10 866 359 5 199 350 16 065 709
(1) Fte/year – full time equivalent per year; O – officials; TA – temporary agents; CA – contract agents; SNE – seconded national experts.
(2) Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP.
(3) Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA mission/task/WP, as their 
immediate aim is to support operational activities and staff. These overheads are distributed to operational activities in proportion of the human resources assigned for the implementation 
of these activities.
D. Support to operations under A, B and C above (overheads)
Objectives and activities Main actors 
for implemen-
tation/ cost 
objects
Allocated human resources  (fte/year) (1) Allocated budget resources for direct cost of supporting 
activities to be distributed to operations (2) (see above) - Non 
assigned appropriations (€)O TA CA SNE Total 
HR
Administration and supporting 
core business
ADM  
(administration 
and resources/
assets  
management)
3 12 7 0 22
4 025 718
ICT (equipment 
and services)
1 7 3 0 11 1 173 632
Total 4 19 10 0 33 5 199 350
(1) Fte/year – full time equivalent per year; O – officials; TA – temporary agents; CA – contract agents; SNE – seconded national experts.
(2) Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA mission/task/WP, as their 
immediate aim is to support operational activities and staff. These overheads are distributed to operational activities in proportion of the human resources assigned for the implementation 
of these activities.
E. Special projects 
(Funded by supplementary appropriations from EU budget on top of the EU regular annual subsidy to the EMCDDA) 
 
Objectives and activities Main actors 
for implemen-
tation/ cost 
objects
Allocated human resources  (fte/year) (1) Allocated budget resources – Non assigned appropriations 
(EUR)
O TA CA SNE Total 
HR
Preparation of IPA Beneficiaries 
Countries for their participation 
in the EMCDDA (IPA 4 project 
– first year)
RTX 2 2
350 000
(1) Fte/year – full time equivalent per year; O – officials; TA – temporary agents; CA – contract agents; SNE – seconded national experts
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Annex II. Estimated allocation/use of the appropriations
Annex III 
List of the national focal points beneficiaries of the 
Reitox grants
Please note that unless there is a reorganisation within the national public administration of 
the beneficiary countries, the beneficiaries of the grant are the same each year. Based on 
the decision of the Management Board of the EMCDDA in December 2007, the maximum 
amount of grant receivable by the focal points is indexed annually by 2% in order to 
maintain the real value of the grant. As such the maximum amount of the grant per country  
in 2012 will be EUR 105 236. The potential beneficiaries for 2012 are:
•	  Gesundheit Österreich GmbH, Stubenring 6; 1010 Wien; Austria
•	  Scientific Institute of Public Health - Patrimoine (IPH - Patrimoine), Rue Juliette Wytsman,  
n° 14; 1050 Brussels; Belgium
•	  National Centre for Addictions (NCA BG), Pirotska str. 117; 1303 Sofia, Bulgaria
•	  Cyprus National Monitoring Centre for Drugs and Drug Addiction - EKTEPN, Antidrugs 
Council, Magnolia Center - Offices 11-12; Strovolos Avenue n° 32; 2018 Nicosia, 
Cyprus
•	 	Úrad	vlády	Ceské	republiky	(Office	of	the	Government	of	the	Czech	Republic),	Nabreží	
Edvarda Beneše n° 4; 118 01 Praha 1 - Malá Strana; Czech Republic
•	  National Board of Health (Sundhedsstyrelsen), Islands Brygge, n° 67; 2300 Copenhagen 
S; Denmark
•	  Tervise Arengu Instituut (National Institute for Health Development - NIHD), Hiiu Street  
n° 42; 11619 Tallinn; Estonia
•	  National Institute for Health and Welfare (THL), Mannerheimintie 166; 00271 Helsinki; 
Finland
•	  Observatoire Français des Drogues et des Toxicomanies (OFDT), Avenue du Stade de 
France 3; 93218 Saint Denis La Plaine Cedex; France
•	  Institut für Therapieforschung (IFT), Parzivalstrasse 25; 80804 Munich; Germany
•	  University Mental Health Research Institute - Greek Reitox Focal Point (UMHRI), 2,  
Soranou tou Efesiou, Papagou; 115 27 Athens; Greece
•	  Országos Epidemiológiai Központ (National Center for Epidemiology), Gyáli út n° 2-6; 
1097 Budapest; Hungary
•	  Health Research Board (HRB), Lower Baggot Street 73; Dublin 2; Éire / Ireland
•	  Presidenza del Consiglio dei Ministri – Dipartimento Politiche Antidroga, Via Po 16/A; 
00198 Roma; Italy
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•	  Veselibas Ekonomikas Centrs - The Centre of Health Economics (CHE), Duntes Street  
No. 12/22 LV-1005 Riga; Latvia
•	  Drug, Tobacco and Alcohol Control Department, Šv. Stepono n° 27; 01312 Vilnius; 
Lithuania
•	  Centre de Recherche Public - Santé (CRP-Santé), Rue Dicks 18; 1417 Luxembourg;  
Grand Duchy of Luxembourg
•	  Ministry for the Family and Social Solidarity (MFSS), Republic Street; Palazzo Ferreria; 
CMR02 Valletta; Malta
•	  Stichting Trimbos-Instituut, Da Costakade, n° 45; 3521 VS Utrecht; the Netherlands
•	  Krajowe Biuro Do Spraw Przeciwdzialania Narkomanii (National Bureau for Drug 
Prevention — Polish National Focal Point), ul. Dereniowa n° 52-54; 02-776 Warsaw; 
Poland
•	  Instituto da Droga e da Toxicodependência (IDT), Praça de Alvalade, n° 7 – 6º;  
1700-036 Lisboa; Portugal
•	  National Anti-drug Agency (NAA) - Unirii Boulevard n° 37, Bl. A4; 3rd district; 030823 
Bucharest; Romania 
•	  Úrad vlády Slovenskej republiky (Office of the Government of the Slovak Republic), 
Námestie slobody n° 1; 813 70 Bratislava; Slovak Republic
•	  Inštitut za Varovanje Zdravja Republike Slovenije (Institute of Public Health of the 
Republic of Slovenia), Trubarjeva n° 2; 1000 Ljubljana; Slovenia
•	  Government Delegation for the National Plan on Drugs, Calle Recoletos 22; 28001 
Madrid; Spain
•	  National Institute of Public Health - Statens Folkhälsoinstitut (FHI), SE 831 40 Östersund; 
Sweden
•	  Department of Health, Waterloo Road, Wellington House 133-155, London SE1 8UG, 
United Kingdom
Annex IV 
Template of the 2012 Reitox grant agreement
http://www.emcdda.europa.eu/about/partners/reitox-network
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Abbreviations and acronyms
ABB Activity-based budgeting HIPP Health in Prisons Project
ABM Activity-based management HNFP Head of National Focal Point
BCP Business continuity plan HoU Heads of Unit
BPP Best practice portal HSR Health and social responses
CC Candidate countries IAS Internal Audit Service
CEPOL European Police College IATE Inter Active Terminology for 
Europe
CICAD Inter-American Drug Abuse Control 
Commission
IDU Injecting drug use
CMA Content Management Application IPA Instrument for Pre-Accession  
Assistance
CoE Council of Europe ISAJE International Society of Addiction 
Journal Editors
COSI Standing Committee on Internal Security KI Key indicator 
CUP Cross-unit project MS Member States
DRD Drug-related deaths MSM Men having sex with men
DRID Drug-related infectious diseases NDO National Drugs Observatory
EDDRA European drug demand reduction action NDIS National Drugs Information 
System
EC European Commission NIDA National Institute on Drug Abuse
ECDC European Centre for Disease Prevention 
and Control
NFP National focal point
EDND European database on new drugs OAS Organization of American States
EHEA European Higher Education Area PCCS Potential candidate countries
EIB Evaluation instruments bank PDU Problem drug use
ELDD European legal database on drugs PDU-R Problem drug use revised
EMA European Medicines Agency PERK Prevention evaluation resources 
kit
EMIS European MSM Internet Survey PG Pompidou Group
ENP European neighbourhood policy RRT Rapid response team
ESPAD European School Survey Project on 
Alcohol and Other Drugs
SC Scientific Committee
EWS Early warning system SEM Environmental Management 
System
EQUS EU framework for minimum quality 
standards and benchmarks in drug 
demand reduction
SR Special registries
EUSPR European Society for Prevention  
Research
SRT Systemic review of tools
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GPS General population survey TDI Treatment demand indicator
HDG Horizontal Drugs Group UNODC United Nations Office on Drugs 
and Crime
HBSC Health behaviour in school-aged 
children
WHO World Health Organisation
HCV Hepatitis C virus
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European Monitoring Centre for Drugs and Drug Addiction
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Luxembourg: Publications Office of the European Union
2012 — 76 pp. — 21 x 29.7 cm
ISBN: 978-92-9168-497-7 
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information on 
drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, 
reliable and comparable information on drugs and drug addiction. In doing 
so, it provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide range 
of audiences including policymakers and their advisers, professionals and 
researchers working in the field of drugs, and, more broadly, the media and 
general public.
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